

NEWS 44 Jun 20 2003 edition of the FSTA Thesaurus is now available
NEWS 45 Jun 25 HSDB has been reloaded

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 15:19:02 ON 07 JUL 2003

```
=> file regt
'REGT' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'HOME'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available. If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
```

FILE 'REGISTRY' ENTERED AT 15:19:14 ON 07 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 JUL 2003 HIGHEST RN 543672-54-4
DICTIONARY FILE UPDATES: 6 JUL 2003 HIGHEST RN 543672-54-4

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s pantothenic acid

AN 1990:232458 CAPLUS
DN 112:232458
TI Screening of anti-**HIV** activities in existing drugs which are suitable for long-term oral administration
AU Asanaka, Miyuki; Kurimura, Takashi; Toya, Harumasa; Kato, Keiko
CS Sch. Med., Tottori Univ., Yonago, 683, Japan
SO Chemotherapy (Tokyo) (1990), 38(3), 249-55
CODEN: NKRZAZ; ISSN: 0009-3165
DT Journal
LA English
CC 10-5 (Microbial Biochemistry)
AB Anti-**HIV** activities of 58 com. drugs available for long-term administration without significant side effects were investigated. Lorazepam, Ca hopanenate, prochlorperazine maleate, amantadine HCl, perphenazine (I) and nitrazepam (II) were found to exhibit anti-**HIV** activity in MT-4 cells. But only I and II did so without cytotoxicity. In peripheral blood mononuclear cells, I exhibited only weak anti-**HIV** activity, while II showed none.
ST AIDS **HIV** virus drug screening perphenazine
IT Virucides and Virustats
(for AIDS treatment, screening of)
IT Immunodeficiency
(acquired immune deficiency syndrome, perphenazine and other drugs for treatment of)
IT Virus, animal
(human immunodeficiency 1, perphenazine and other drugs effect on)
IT 58-39-9, Perphenazine 84-02-6, Prochlorperazine maleate 146-22-5, Nitrazepam 665-66-7, Amantadine hydrochloride 846-49-1, Lorazepam 17097-76-6, Calcium hopanenate
RL: BIOL (Biological study)
(anti-**HIV** virus activity of, cytotoxicity in relation to)

=>

RN 17097-76-6 REGISTRY

CN Butanoic acid, 4-[(2R)-2,4-dihydroxy-3,3-dimethyl-1-oxobutyl]amino]-, calcium salt (2:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Butanoic acid, 4-[(2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)amino]-, calcium salt (2:1), (R)-

CN Butyric acid, 4-(2,4-dihydroxy-3,3-dimethylbutyramido)-, calcium salt (2:1), D-(+)- (8CI)

OTHER NAMES:

CN Calcium D-(+)-homopantothenate

CN Calcium D-homopantothenate

CN Calcium homopantothenate

CN Calcium hopantenate

CN D-(+)-Homopantothenic acid calcium salt

CN Hopantenate calcium

CN Pantogam

CN Vivant

FS STEREOSEARCH


MF C10 H19 N 05 . 1/2 Ca

CI COM

LC STN Files: ADISNEWS, AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, DDFU, DRUGU, EMBASE, IPA, PHAR, PHARMASEARCH, PROMT, RTECS*, TOXCENTER, USAN
(*File contains numerically searchable property data)

CRN (18679-90-8)

Absolute stereochemistry.



● 1/2 Ca

115 REFERENCES IN FILE CA (1957 TO DATE)

115 REFERENCES IN FILE CAPLUS (1957 TO DATE)

Welcome to STN International! Enter x:x

LOGINID:sssptaul25rxt

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 Jun 03 New e-mail delivery for search results now available
NEWS 4 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 5 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 6 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 7 Sep 03 JAPIO has been reloaded and enhanced
NEWS 8 Sep 16 Experimental properties added to the REGISTRY file
NEWS 9 Sep 16 CA Section Thesaurus available in CAPLUS and CA
NEWS 10 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 11 Oct 24 BEILSTEIN adds new search fields
NEWS 12 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 13 Nov 18 DKILIT has been renamed APOLLIT
NEWS 14 Nov 25 More calculated properties added to REGISTRY
NEWS 15 Dec 04 CSA files on STN
NEWS 16 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 17 Dec 17 TOXCENTER enhanced with additional content
NEWS 18 Dec 17 Adis Clinical Trials Insight now available on STN
NEWS 19 Jan 29 Simultaneous left and right truncation added to COMPENDEX,
ENERGY, INSPEC
NEWS 20 Feb 13 CANCERLIT is no longer being updated
NEWS 21 Feb 24 METADEX enhancements
NEWS 22 Feb 24 PCTGEN now available on STN
NEWS 23 Feb 24 TEMA now available on STN
NEWS 24 Feb 26 NTIS now allows simultaneous left and right truncation
NEWS 25 Feb 26 PCTFULL now contains images
NEWS 26 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 27 Mar 20 EVENTLINE will be removed from STN
NEWS 28 Mar 24 PATDPAFULL now available on STN
NEWS 29 Mar 24 Additional information for trade-named substances without
structures available in REGISTRY
NEWS 30 Apr 11 Display formats in DGENE enhanced
NEWS 31 Apr 14 MEDLINE Reload
NEWS 32 Apr 17 Polymer searching in REGISTRY enhanced
NEWS 33 Jun 13 Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS 34 Apr 21 New current-awareness alert (SDI) frequency in
WPIDS/WPINDEX/WPIX
NEWS 35 Apr 28 RDISCLOSURE now available on STN
NEWS 36 May 05 Pharmacokinetic information and systematic chemical names
added to PHAR
NEWS 37 May 15 MEDLINE file segment of TOXCENTER reloaded
NEWS 38 May 15 Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 39 May 16 CHEMREACT will be removed from STN
NEWS 40 May 19 Simultaneous left and right truncation added to WSCA
NEWS 41 May 19 RAPRA enhanced with new search field, simultaneous left and
right truncation
NEWS 42 Jun 06 Simultaneous left and right truncation added to CBNB
NEWS 43 Jun 06 PASCAL enhanced with additional data


104 PANTOTHENIC
5972582 ACID
L1 101 PANTOTHENIC ACID
(PANTOTHENIC (W) ACID)

=> s vitamin b5
1477 VITAMIN
1478 B5
L2 2 VITAMIN B5
(VITAMIN (W) B5)

=> d 12 1-2

L2 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2003 ACS
RN 137-08-6 REGISTRY
CN .beta.-Alanine, N-[(2R)-2,4-dihydroxy-3,3-dimethyl-1-oxobutyl]-, calcium salt (2:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN .beta.-Alanine, N-(2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)-, calcium salt (2:1), (R)-
CN Calcium, bis(pantothenato)- (7CI)
CN Pantothenic acid, calcium salt (2:1), D- (8CI)
OTHER NAMES:
CN (+)-Pantothenic acid calcium salt
CN Calcium D-(+)-N-(.alpha.,.gamma.-dihydroxy-.beta.,.beta.-dimethylbutyryl)-.beta.-alaninate
CN Calcium D-(+)-pantothenate
CN Calcium D-pantothenate
CN Calcium pantothenate
CN Calpan
CN Calpanate
CN Dextro calcium pantothenate
CN N-(2,4-Dihydroxy-3,3-dimethylbutyryl)-.beta.-alanine calcium
CN Pancal
CN Panthoject
CN Pantholin
CN Pantothenate calcium
CN Pantothenic acid calcium salt
CN Pantothenic acid hemicalcium salt
CN **Vitamin B5 calcium salt**
FS STEREOSEARCH
DR 7693-16-5, 533-61-9, 138932-10-2
MF C9 H17 N 05 . 1/2 Ca
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, TOXCENTER, TULSA, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)
CRN (79-83-4)

Absolute stereochemistry. Rotation (+).




●1/2 Ca

1164 REFERENCES IN FILE CA (1957 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1165 REFERENCES IN FILE CAPLUS (1957 TO DATE)
 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L2 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2003 ACS
 RN 79-83-4 REGISTRY
 CN .beta.-Alanine, N-[(2R)-2,4-dihydroxy-3,3-dimethyl-1-oxobutyl]- (9CI) (CA
 INDEX NAME)
 OTHER CA INDEX NAMES:
 CN .beta.-Alanine, N-(2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)-, (R)-
 CN Pantothenic acid, D- (8CI)
 OTHER NAMES:
 CN (+)-Pantothenic acid
 CN (D)-(+)-Pantothenic acid
 CN Chick antidermatitis factor
 CN D(+)-N-(2,4-Dihydroxy-3,3-dimethylbutyryl)-.beta.-alanine
 CN D-Pantothenic acid
 CN Pantothenic acid
 CN Vitamin B3
 CN **Vitamin B5**
 FS STEREOSEARCH
 DR 3563-85-7
 MF C9 H17 N 05
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
 BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS,
 CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE,
 HODOC*, HSDB*, IFICDB, IFIUDB, IPA, MEDLINE, MRCK*, NAPRALERT, NIOSHTIC,
 PIRA, PROMT, RTECS*, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
 (*File contains numerically searchable property data)
 Other Sources: EINECS**
 (**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4401 REFERENCES IN FILE CA (1957 TO DATE)

125 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
4405 REFERENCES IN FILE CAPLUS (1957 TO DATE)
8 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s vitamin b3
1477 VITAMIN
2455 B3
L3 2 VITAMIN B3
(VITAMIN (W) B3)


=> d 12 not 13
L3 IS NOT VALID HERE
For an explanation, enter "HELP DISPLAY".

=> s 12 not 13
L4 1 L2 NOT L3

=> d 14

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
RN 137-08-6 REGISTRY
CN .beta.-Alanine, N-[(2R)-2,4-dihydroxy-3,3-dimethyl-1-oxobutyl]-, calcium salt (2:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN .beta.-Alanine, N-(2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)-, calcium salt (2:1), (R)-
CN Calcium, bis(pantothenato)- (7CI)
CN Pantothenic acid, calcium salt (2:1), D- (8CI)
OTHER NAMES:
CN (+)-Pantothenic acid calcium salt
CN Calcium D-(+)-N-(.alpha.,.gamma.-dihydroxy-.beta.,.beta.-dimethylbutyryl)-.beta.-alaninate
CN Calcium D-(+)-pantothenate
CN Calcium D-pantothenate
CN Calcium pantothenate
CN Calpan
CN Calpanate
CN Dextro calcium pantothenate
CN N-(2,4-Dihydroxy-3,3-dimethylbutyryl)-.beta.-alanine calcium
CN Pancal
CN Panthoject
CN Pantholin
CN Pantothenate calcium
CN Pantothenic acid calcium salt
CN Pantothenic acid hemicalcium salt
CN **Vitamin B5 calcium salt**
FS STEREOSEARCH
DR 7693-16-5, 533-61-9, 138932-10-2
MF C9 H17 N 05 . 1/2 Ca
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS*, TOXCENTER, TULSA, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)
CRN (79-83-4)

Absolute stereochemistry. Rotation (+).



● 1/2 Ca

1164 REFERENCES IN FILE CA (1957 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1165 REFERENCES IN FILE CAPLUS (1957 TO DATE)
 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

| => file caplus | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| COST IN U.S. DOLLARS | | |
| FULL ESTIMATED COST | 31.16 | 31.37 |

FILE 'CAPLUS' ENTERED AT 15:20:40 ON 07 JUL 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Jul 2003 VOL 139 ISS 2
 FILE LAST UPDATED: 6 Jul 2003 (20030706/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 15:19:02 ON 07 JUL 2003)

FILE 'REGISTRY' ENTERED AT 15:19:14 ON 07 JUL 2003

| | |
|----|------------------------|
| L1 | 101 S PANTOTHENIC ACID |
| L2 | 2 S VITAMIN B5 |
| L3 | 2 S VITAMIN B3 |
| L4 | 1 S L2 NOT L3 |

FILE 'CAPLUS' ENTERED AT 15:20:40 ON 07 JUL 2003

| | |
|---------|---------|
| => s 11 | |
| L5 | 5882 L1 |

```

=> e retroviral
E1      15      RETROVIAL/BI
E2      34      RETROVIR/BI
E3      13558 --> RETROVIRAL/BI
E4      1      RETROVIRALES/BI
E5      683      RETROVIRALLY/BI
E6      9      RETROVIRALS/BI
E7      1      RETROVIRALVECTOR/BI
E8      5      RETROVIREMIA/BI
E9      1      RETROVIREMIC/BI
E10     1      RETROVIRES/BI
E11     1      RETROVIRIAL/BI
E12     1      RETROVIRICIDAL/BI

=> s e1-e6
      15 RETROVIAL/BI
      34 RETROVIR/BI
      13558 RETROVIRAL/BI
      1 RETROVIRALES/BI
      683 RETROVIRALLY/BI
      9 RETROVIRALS/BI
L6      13948 (RETROVIAL/BI OR RETROVIR/BI OR RETROVIRAL/BI OR RETROVIRALES/BI
      OR RETROVIRALLY/BI OR RETROVIRALS/BI)

=> s hiv
L7      50063 HIV

=> s l7 or l6
L8      61642 L7 OR L6

=> d his

(FILE 'HOME' ENTERED AT 15:19:02 ON 07 JUL 2003)

FILE 'REGISTRY' ENTERED AT 15:19:14 ON 07 JUL 2003
L1      101 S PANTOTHENIC ACID
L2      2 S VITAMIN B5
L3      2 S VITAMIN B3
L4      1 S L2 NOT L3

FILE 'CPLUS' ENTERED AT 15:20:40 ON 07 JUL 2003
L5      5882 S L1
      E RETROVIRAL
L6      13948 S E1-E6
L7      50063 S HIV
L8      61642 S L7 OR L6

=> s 15 and 18
L9      8 L5 AND L8

=> d 19 1-8

L9      ANSWER 1 OF 8 CPLUS COPYRIGHT 2003 ACS
AN      2003:76964 CPLUS
DN      138:133150
TI      Human pantothenate kinase and cDNA and methods for diagnosing
      predisposition to and treating of neurodegenerative disorders
IN      Hayflick, Susan J.; Gitschier, Jane; Zhou, Bing; Westaway, Shawn;
      Levinson, Barbara; Johnson, Monique
PA      Oregon Health and Science University, USA; The Regents of the University
      of California
SO      PCT Int. Appl., 143 pp.

```

CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2003008626 | A2 | 20030130 | WO 2002-US22952 | 20020719 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| PRAI | US 2001-307081P | P | 20010720 | | |
| | US 2001-308055P | P | 20010725 | | |

L9 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2003 ACS

AN 2002:745859 CAPLUS

DN 137:277454

TI A pantothenate auxotroph of *Mycobacterium tuberculosis* is highly attenuated and protects mice against tuberculosis

AU Sambandamurthy, Vasan K.; Wang, Xiaojuan; Chen, Bing; Russell, Robert G.; Derrick, Steven; Collins, Frank M.; Morris, Sheldon L.; Jacobs, William R.

CS Howard Hughes Medical Institute, Albert Einstein College of Medicine, Bronx, NY, USA

SO Nature Medicine (New York, NY, United States) (2002), 8(10), 1171-1174
CODEN: NAMEFI; ISSN: 1078-8956

PB Nature Publishing Group

DT Journal

LA English

RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2003 ACS

AN 2002:293978 CAPLUS

DN 136:337341

TI Materials and methods to modulate ligand binding/enzymic activity of .alpha./.beta. proteins containing an allosteric regulatory site

IN Stauton, Donald E.

PA Icos Corporation, USA

SO PCT Int. Appl., 163 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | WO 2002031511 | A2 | 20020418 | WO 2001-US32047 | 20011012 |
| | WO 2002031511 | A3 | 20030313 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, | | | | |

BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2002013196 A5 20020422 AU 2002-13196 20011012
 US 2003088061 A1 20030508 US 2001-976935 20011012
 PRAI US 2000-239750P P 20001012
 WO 2001-US32047 W 20011012

L9 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2003 ACS
 AN 2001:570199 CAPLUS
 DN 136:35788
 TI A novel pantothenate kinase gene (PANK2) is defective in
 Hallervorden-Spatz syndrome
 AU Zhou, Bing; Westaway, Hawn K.; Levinson, Barbara; Johnson, Monique A.;
 Gitschier, Jane; Hayflick, Susan J.
 CS Howard Hughes Medical Institute and Departments of Medicine and
 Pediatrics, University of California, Parnassus, CA, 94143, USA
 SO Nature Genetics (2001), 28(4), 345-349
 CODEN: NGENEC; ISSN: 1061-4036
 PB Nature America Inc.
 DT Journal
 LA English
 RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2003 ACS
 AN 2001:6065 CAPLUS
 DN 134:37051
 TI Method for immune-system strengthening and development of a lipid
 transporter for anti-HIV and antibacterial gene therapy
 IN Worm, Richard; Correa, Michel; Mavoungou, Donatien
 PA Can.
 SO Fr. Demande, 16 pp.
 CODEN: FRXXBL
 DT Patent
 LA French
 FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-------------------|------|----------|-----------------|----------|
| PI FR 2792201 | A1 | 20001020 | FR 1999-4706 | 19990415 |
| FR 2792201 | B1 | 20011102 | | |
| PRAI FR 1999-4706 | | 19990415 | | |

L9 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2003 ACS
 AN 1998:661494 CAPLUS
 DN 129:298375
 TI Antimicrobial prevention and treatment of human immunodeficiency virus and
 other infectious diseases
 IN Squires, Meryl
 PA USA
 SO PCT Int. Appl., 99 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 5

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| PI WO 9842188 | A1 | 19981001 | WO 1998-US5792 | 19980324 |
| W: | AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG,
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| RW: | GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, | | | |

FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
 GA, GN, ML, MR, NE, SN, TD, TG

| | | | | |
|--|----------------|----------|----------------|----------|
| US 6350784 | B1 | 20020226 | US 1997-824041 | 19970326 |
| AU 9867718 | A1 | 19981020 | AU 1998-67718 | 19980324 |
| AU 727339 | B2 | 20001207 | | |
| BR 9807892 | A | 20000222 | BR 1998-7892 | 19980324 |
| EP 980203 | A1 | 20000223 | EP 1998-913086 | 19980324 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO | | | | |
| EE 9900436 | A | 20000417 | EE 1999-436 | 19980324 |
| NZ 500002 | A | 20010928 | NZ 1998-500002 | 19980324 |
| JP 2001527541 | T2 | 20011225 | JP 1998-545926 | 19980324 |
| NO 9904639 | A | 19991124 | NO 1999-4639 | 19990924 |
| MX 9908750 | A | 20000331 | MX 1999-8750 | 19990924 |
| BG 63612 | B1 | 20020731 | BG 1999-103786 | 19991007 |
| PRAI | US 1997-824041 | A | 19970326 | |
| | US 1996-600217 | A2 | 19960212 | |
| | US 1996-646988 | A2 | 19960508 | |
| | WO 1998-US5792 | W | 19980324 | |

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2003 ACS
 AN 1990:610545 CAPLUS
 DN 113:210545
 TI Micronutrient status and human immunodeficiency virus (**HIV**)
 infection
 AU Bogden, John D.; Baker, Herman; Frank, Oscar; Perez, George; Kemp,
 Francis; Bruening, Kay; Louria, Donald
 CS New Jersey Med. Sch., Univ. Med. Dent., Newark, NJ, 07103-2757, USA
 SO Annals of the New York Academy of Sciences (1990), 587(Micronutr. Immune
 Funct./Cytokines Metab.), 189-95
 CODEN: ANYAA9; ISSN: 0077-8923
 DT Journal
 LA English

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2003 ACS
 AN 1990:232458 CAPLUS
 DN 112:232458
 TI Screening of anti-**HIV** activities in existing drugs which are
 suitable for long-term oral administration
 AU Asanaka, Miyuki; Kurimura, Takashi; Toya, Harumasa; Kato, Keiko
 CS Sch. Med., Tottori Univ., Yonago, 683, Japan
 SO Chemotherapy (Tokyo) (1990), 38(3), 249-55
 CODEN: NKRZAZ; ISSN: 0009-3165
 DT Journal
 LA English

=> d 19 6 7 8 all

L9 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2003 ACS
 AN 1998:661494 CAPLUS
 DN 129:298375
 TI Antimicrobial prevention and treatment of human immunodeficiency virus and
 other infectious diseases
 IN Squires, Meryl
 PA USA
 SO PCT Int. Appl., 99 pp.
 CODEN: PIXXD2
 DT Patent
 LA English

IC ICM A01N033-12

ICS A61K031-14

CC 1-5 (Pharmacology)

Section cross-reference(s): 63

FAN.CNT 5

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9842188 | A1 | 19981001 | WO 1998-US5792 | 19980324 |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | US 6350784 | B1 | 20020226 | US 1997-824041 | 19970326 |
| | AU 9867718 | A1 | 19981020 | AU 1998-67718 | 19980324 |
| | AU 727339 | B2 | 20001207 | | |
| | BR 9807892 | A | 20000222 | BR 1998-7892 | 19980324 |
| | EP 980203 | A1 | 20000223 | EP 1998-913086 | 19980324 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | EE 9900436 | A | 20000417 | EE 1999-436 | 19980324 |
| | NZ 500002 | A | 20010928 | NZ 1998-500002 | 19980324 |
| | JP 2001527541 | T2 | 20011225 | JP 1998-545926 | 19980324 |
| | NO 9904639 | A | 19991124 | NO 1999-4639 | 19990924 |
| | MX 9908750 | A | 20000331 | MX 1999-8750 | 19990924 |
| | BG 63612 | B1 | 20020731 | BG 1999-103786 | 19991007 |
| PRAI | US 1997-824041 | A | 19970326 | | |
| | US 1996-600217 | A2 | 19960212 | | |
| | US 1996-646988 | A2 | 19960508 | | |
| | WO 1998-US5792 | W | 19980324 | | |
| AB | An improved medical treatment and medicine is provided to quickly and safely resolve HIV and other microbial infections. The inexpensive medicine can be self administered and maintained for the prescribed time. The attractive medicine comprises an antimicrobial conc. comprising microbe inhibitors, phytochems. or isolates. Desirably, the effective medicine comprises a surfactant and an aq. carrier or solvent and a nutrient. In the preferred form, the medicine comprises: Echinacea and Commiphora myrrha phytochems., benzalkonium chloride, a sterile water soln., and folic acid. | | | | |
| ST | phytochem nutrient antimicrobial HIV ; Echinacea Commiphora phytochem surfactant antimicrobial HIV ; folic acid phytochem antimicrobial HIV | | | | |
| IT | Labia | | | | |
| | Lip | | | | |
| | Lymph node | | | | |
| | Lymphatic system | | | | |
| | T cell (lymphocyte) | | | | |
| | (administration to; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases) | | | | |
| IT | Quaternary ammonium compounds, biological studies | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | | |
| | (alkylbenzyldimethyl, bromides; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases) | | | | |
| IT | Quaternary ammonium compounds, biological studies | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | | |
| | (alkylbenzyldimethyl, chlorides; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases) | | | | |
| IT | Surfactants | | | | |
| | (amphoteric; antimicrobial prevention and treatment of human | | | | |

immunodeficiency virus and other infectious diseases)
IT Bacilli
(anaerobic; antimicrobial prevention and treatment of human
immunodeficiency virus and other infectious diseases)
IT Allium
Anise
Arctostaphylos
Artemisia
Baptisia
Calendula
Capsicum
Carum
Compositae (Asteraceae)
Coriandrum
Echinacea angustifolia
Echinacea atribactilus
Echinacea pallida
Echinacea purpurea
Echinacea vegetalis
Eucalyptus
Eugenia mytacea
Gentian (Gentiana)
Inula
Juniper (Juniperus)
Labiatae (Lamiaceae)
Melirosma
Mentha
Mentha aquatica hypeuria
Myroxylon
Origanum
Parthenium integrifolium
Plantago
Rosemary
Ruta
Sage (Salvia)
(antimicrobial isolates of; antimicrobial prevention and treatment of
human immunodeficiency virus and other infectious diseases)
IT Adenoviridae
Antibacterial agents
Antimicrobial agents
Antiviral agents
Arbovirus
Arenavirus
Bird (Aves)
Cat (Felis catus)
Cattle
Commiphora erythraea
Commiphora molmol
Commiphora myrrha
Coronavirus
Cytomegalovirus
Dog (Canis familiaris)
Drug delivery systems
Gums and Mucilages
Horse (Equus caballus)
Human herpesvirus 1
Human herpesvirus 2
Human herpesvirus 3
Human herpesvirus 4
Human immunodeficiency virus
Human parainfluenza virus
Influenza virus

Livestock
Mycobacterium
Nutrients
Papillomavirus
Picornaviridae
Rodent
Sexually transmitted diseases
Sheep
Staphylococcus
Streptococcus
Surfactants
Swine
 (antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Amides, biological studies
Anthocyanins
Enzymes, biological studies
Natural products, pharmaceutical
Polyacetylenes, biological studies
Polysaccharides, biological studies
Proteins, general, biological studies
Sesquiterpenes
Tannins
Vitamins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Encephalitis
Meningitis
 (bacterial and viral; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Detergents
Surfactants
 (cationic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Inflammation
 (cellulitis; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Polyacetylenes, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (derivs.; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Vitamins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (fat-sol.; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
 (injections; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Mouth
 (mucosa, administration to; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
 (nasal; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Surfactants

(nonionic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(ophthalmic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Animal tissue
(periacinal, administration to; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Plant (Embryophyta)
(phytochems.; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Intestine
(rectum, anus, administration to; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(sublingual; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(surfactant; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Carboxylic acids, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetraenoic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(topical, and systemic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(vaginal; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Vitamins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(water-sol.; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Surfactants
(zwitterionic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT 50-81-7, Ascorbic acid, biological studies 57-10-3, Hexadecanoic acid, biological studies 57-88-5, Cholesterol, biological studies 58-86-6, Xylose, biological studies 59-23-4, Galactose, biological studies 59-30-3, Folic acid, biological studies 59-43-8, Thiamin, biological studies 59-67-6, Niacin, biological studies 64-19-7, Acetic acid, biological studies 68-19-9, Vitamin B12 76-49-3, Bornyl acetate 79-83-4, Vitamin B5 80-56-8, .alpha.-Pinene 83-46-5, .beta.-Sitosterol 83-48-7, Stigmasterol 83-88-5, Riboflavin, biological studies 87-44-5, Caryophyllene 87-69-4, biological studies 97-53-0, Eugenol 104-55-2, Cinnamaldehyde 108-39-4, biological studies 112-85-6D, Docosanoic acid, derivs. 117-39-5, Quercetin 121-33-5, Vanillin 122-03-2, Cuminaldehyde 127-91-3, .beta.-Pinene 138-86-3, Limonene 147-81-9, Arabinose 153-18-4, Rutin 327-97-9, Chlorogenic acid 331-39-5, Caffeic acid 331-39-5D, Caffeic acid, esters 474-58-8 474-62-4, Campesterol 480-10-4, Kaempferol-3-glucoside 482-35-9, Quercetin-3-glucoside 482-36-0 491-70-3, Luteolin 495-62-5, .gamma.-Bisabolene 504-97-2, Echinacein 507-70-0, Borneol 520-18-3, Kaempferol 520-36-5, Apigenin 534-61-2, Isochlorogenic acid 536-60-7, Cumaric alcohol 548-75-4, Quercetagetin-7-glucoside 563-83-7

593-50-0, n-Triacontanol 604-80-8 638-96-0, .alpha.-Amyrone
 639-99-6, Elemol 643-20-9D, Pyrrolizidine, alkaloid 1139-30-6,
 Caryophyllene epoxide 1406-16-2, Vitamin D 1406-18-4, Vitamin E
 2450-53-5, 3,5-Dicaffeoylquinic acid 3562-36-5, Pontica epoxide
 3615-41-6, Rhamnose 3812-32-6, Carbonate, biological studies
 3943-97-3, Methyl p-hydroxycinnamate 4120-73-4, 4-O-Methylglucuronic
 acid 5373-11-5, Luteolin-7-glucoside 5937-48-4, 3-epi-.alpha.-Amyrin
 6537-80-0, Chicoric acid 6556-12-3, Glucuronic acid 7235-40-7,
 .beta.-Carotene 7439-89-6, Iron, biological studies 7439-95-4,
 Magnesium, biological studies 7439-96-5, Manganese, biological studies
 7440-09-7, Potassium, biological studies 7440-23-5, Sodium, biological
 studies 7440-48-4, Cobalt, biological studies 7440-70-2, Calcium,
 biological studies 7723-14-0, Phosphorus, biological studies
 7782-49-2, Selenium, biological studies 8001-18-1, Echinacin
 8059-24-3, Vitamin B6 9005-80-5, Inulin 9014-63-5D, Xylan, derivs.
 9036-66-2, Arabinogalactan 9040-28-2, 4-O-Methylglucuronoolarabinopyran
 11006-56-7, Vitamin B15 11103-57-4, Vitamin A 12001-79-5, Vitamin K
 12627-13-3, Silicate 13360-61-7, 1-Pentadecene 14808-79-8, Sulfate,
 biological studies 16887-00-6, Chloride, biological studies
 17627-44-0, .alpha.-Bisabolene 17650-84-9 18668-90-1,
 8-Pentadecen-2-one 18794-84-8, .beta.-Farnesene 19912-61-9,
 Furanodiene 20493-56-5, Curzerenone 23986-74-5, Germacrene D
 24268-41-5, Furanodienone 24738-51-0 25067-58-7, Polyacetylene
 25067-58-7D, Polyacetylene, derivs. 27214-55-7, Quercetin-3-xyloside
 28028-64-0, Germacrene 29350-73-0, Cadinene 30964-13-7, Cynarin
 36129-21-2 39007-92-6, Commiferin 47705-70-4 52525-35-6 57378-72-0
 59440-97-0, Echinolone 61276-17-3, Verbascoside 67879-58-7
 69350-61-4, Epishybunol 74282-22-7 75081-19-5, Pentadecadiene
 76963-26-3 80151-77-5, Tussilagine 82854-37-3, Echinacoside
 84744-28-5 91108-32-6, Isotussilagine 94977-38-5 99119-75-2
 99119-76-3 116752-09-1 116752-10-4 117841-81-3 118853-85-3
 125199-93-1 148879-89-4, Commiphorinic acid 149531-55-5,
 .alpha.-Commiphoric acid 149531-56-6, .beta.-Commiphoric acid
 149531-57-7, .gamma.-Commiphoric acid 162666-19-5, Inuloidin
 205510-62-9, Echinacin B 214041-69-7 214041-70-0 214041-71-1
 214041-72-2 214041-73-3 214405-10-4, Heerabolene 214405-11-5,
 .alpha.-Heerabomyrrhol 214405-12-6, .beta.-Heerabomyrrhol 214405-13-7,
 Heeraboresene 214405-44-4, Viracea 1 214405-45-5, Viracea 2
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)

(antimicrobial prevention and treatment of human immunodeficiency virus
 and other infectious diseases)

IT 120-32-1, o-Benzyl-p-chlorophenol 139-07-1, Lauryldimethylbenzylammonium
 chloride 5538-94-3, Dioctyldimethylammonium chloride 7173-51-5,
 Didecyldimethylammonium chloride 32426-11-2, Octyldecyldimethylammonium
 chloride

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antimicrobial prevention and treatment of human immunodeficiency virus
 and other infectious diseases)

IT 12001-76-2, Vitamin B

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)

(complex; antimicrobial prevention and treatment of human
 immunodeficiency virus and other infectious diseases)

IT 79-14-1D, Glycolic acid, derivs.

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(surfactant; antimicrobial prevention and treatment of human
 immunodeficiency virus and other infectious diseases)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE

- (1) Bryant; US 4797420 A 1989 CAPLUS
- (2) Hempel; DE 3521143 A1 CAPLUS Acc No 1987:483909 1986 CAPLUS
- (3) Silverman; US 5455033 A 1995
- (4) Tyle, R; "The Honest Herbal, A Sensible Guide to the Use of Herbs and Related Remedies", 3rd Edition 1993, P115
- (5) Tyler, V; Herbs of choice, The Therapeutic Use of Phytomedicinals 1994, P181
- (6) Wainberg; Arch AIDS Res, CAPLUS Acc No 1988:147004 1987, V1(1), P57 CAPLUS

L9 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2003 ACS
 AN 1990:610545 CAPLUS
 DN 113:210545
 TI Micronutrient status and human immunodeficiency virus (**HIV**) infection
 AU Bogden, John D.; Baker, Herman; Frank, Oscar; Perez, George; Kemp, Francis; Bruening, Kay; Louria, Donald
 CS New Jersey Med. Sch., Univ. Med. Dent., Newark, NJ, 07103-2757, USA
 SO Annals of the New York Academy of Sciences (1990), 587(Micronutr. Immune Funct./Cytokines Metab.), 189-95
 CODEN: ANYAA9; ISSN: 0077-8923
 DT Journal
 LA English
 CC 18-1 (Animal Nutrition)
 Section cross-reference(s): 14, 15
 AB Humans with **HIV** infections generally showed .gtoreq.1 abnormally low level of plasma micronutrients (e.g. minerals, vitamins). Abnormally high levels of some micronutrients were also found, but these were attributed to the ingestion of high supplement amts.
 ST micronutrient nutrition human immunodeficiency virus infection; **HIV** infection diet micronutrient
 IT Carotenes and Carotenoids, biological studies
 Trace elements, biological studies
 Vitamins
 RL: BIOL (Biological study)
 (HIV virus infection in humans in relation to nutritional status of)
 IT Virus, animal
 (human immunodeficiency 1, humans infection by, micronutrient status in relation to)
 IT Nutrients
 (micro-, **HIV** virus infection in humans in relation to nutritional status of)
 IT 50-81-7, Vitamin C, biological studies 58-85-5, Biotin 59-30-3, Folic acid, biological studies 59-43-8, Thiamin, biological studies 59-67-6, Niacin, biological studies 62-49-7, Choline 68-19-9, Vitamin B12 79-83-4, Pantothenic acid 83-88-5, Riboflavin, biological studies 87-89-8, Inositol 541-15-1, Carnitine 1406-18-4, Vitamin E 7439-95-4, Magnesium, biological studies 7440-50-8, Copper, biological studies 7440-66-6, Zinc, biological studies 7440-70-2, Calcium, biological studies 8059-24-3, Vitamin B6 11103-57-4, Vitamin A 22150-76-1, Biopterin
 RL: BIOL (Biological study)
 (HIV virus infection in humans in relation to nutritional status of)

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2003 ACS
 AN 1990:232458 CAPLUS
 DN 112:232458
 TI Screening of anti-**HIV** activities in existing drugs which are suitable for long-term oral administration
 AU Asanaka, Miyuki; Kurimura, Takashi; Toya, Harumasa; Kato, Keiko
 CS Sch. Med., Tottori Univ., Yonago, 683, Japan

SO Chemotherapy (Tokyo) (1990), 38(3), 249-55
CODEN: NKRZAZ; ISSN: 0009-3165
DT Journal
LA English
CC 10-5 (Microbial Biochemistry)
AB Anti-**HIV** activities of 58 com. drugs available for long-term administration without significant side effects were investigated. Lorazepam, Ca hopantenate, prochlorperazine maleate, amantadine HCl, perphenazine (I) and nitrazepam (II) were found to exhibit anti-**HIV** activity in MT-4 cells. But only I and II did so without cytotoxicity. In peripheral blood mononuclear cells, I exhibited only weak anti-**HIV** activity, while II showed none.
ST AIDS **HIV** virus drug screening perphenazine
IT Virucides and Virustats
(for AIDS treatment, screening of)
IT Immunodeficiency
(acquired immune deficiency syndrome, perphenazine and other drugs for treatment of)
IT Virus, animal
(human immunodeficiency 1, perphenazine and other drugs effect on)
IT 58-39-9, Perphenazine 84-02-6, Prochlorperazine maleate 146-22-5, Nitrazepam 665-66-7, Amantadine hydrochloride 846-49-1, Lorazepam 17097-76-6, Calcium hopantenate
RL: BIOL (Biological study)
(anti-**HIV** virus activity of, cytotoxicity in relation to)

=> s vitamin d
162566 VITAMIN
1998955 D
L10 21260 VITAMIN D
(VITAMIN(W) D)

=> s l10 and l8
L11 33 L10 AND L8

=> d 111 1-33

L11 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2003 ACS
AN 2003:405499 CAPLUS
DN 139:4715
TI Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts
AU Klein, Ulf; Gloghini, Annunziata; Gaidano, Gianluca; Chadburn, Amy; Cesarman, Ethel; Dalla-Favera, Riccardo; Carbone, Antonino
CS Institute for Cancer Genetics, Columbia University, New York, NY, USA
SO Blood (2003), 101(10), 4115-4121
CODEN: BLOOAW; ISSN: 0006-4971
PB American Society of Hematology
DT Journal
LA English

RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 33 CAPLUS COPYRIGHT 2003 ACS
AN 2003:355828 CAPLUS
DN 138:363217
TI Uses of parathyroid hormone antagonists for the diagnosis and treatment of diseases associated with bone mineral loss
IN Cantor, Thomas L.
PA USA

SO U.S. Pat. Appl. Publ., 29 pp., Cont.-in-part of U.S. Ser. No. 928,047.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|------|----------|-----------------|----------|
| PI | US 2003087822 | A1 | 20030508 | US 2002-215770 | 20020809 |
| | US 2002160945 | A1 | 20021031 | US 2001-928047 | 20010810 |
| PRAI | US 1999-323606 | B2 | 19990602 | | |
| | US 2000-224446P | P | 20000810 | | |
| | US 2000-224447P | P | 20000810 | | |
| | US 2000-636530 | A2 | 20000810 | | |
| | US 2001-928047 | A2 | 20010810 | | |

L11 ANSWER 3 OF 33 CAPLUS COPYRIGHT 2003 ACS

AN 2003:335643 CAPLUS

DN 138:315894

TI Protein and cDNA sequences of a 11.88-kilodalton human cytochrome P450 CYP27-like protein and their therapeutic uses

IN Mao, Yumin; Xie, Yi

PA Fudan Univ., Peop. Rep. China; Bodao Gene Technology Co., Ltd., Shanghai

SO Faming Zhuanli Shengqing Gongkai Shuomingshu, 32 pp.

CODEN: CNXXEV

DT Patent

LA Chinese

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|------|----------|-----------------|----------|
| PI | CN 1355304 | A | 20020626 | CN 2000-127547 | 20001124 |
| PRAI | CN 2000-127547 | | | 20001124 | |

L11 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS

AN 2003:301542 CAPLUS

DN 138:286625

TI Relation between micronutrient intakes and CD4 count in **HIV** infected patients

AU de Luis, D. A.; Bachiller, P.; Aller, R.; de Luis, J.; Izaola, O.; Terroba, M. C.; Cuellar, L.; Sagrado, M. Gonzalez

CS Seccion de Endocrinologia y Nutricion Clinica. Unidad de Apoyo a la Investigacion, Hospital Rio Hortega, Valladolid, 47130, Spain

SO Nutricion Hospitalaria (2002), 17(6), 285-289

CODEN: NUHOEQ; ISSN: 0212-1611

PB Aula Medica Ediciones

DT Journal

LA Spanish

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 33 CAPLUS COPYRIGHT 2003 ACS

AN 2003:261603 CAPLUS

DN 138:281598

TI Androstanone compounds as androgen receptor (AR) modulators for the treatment of AR-related diseases

IN Wang, Jiabing

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 83 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|------|-----------------|------|
|------------|------|------|-----------------|------|

PI WO 2003026568 A2 20030403 WO 2002-US29436 20020917

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-324124P P 20010921

OS MARPAT 138:281598

L11 ANSWER 6 OF 33 CAPLUS COPYRIGHT 2003 ACS

AN 2003:241921 CAPLUS

DN 138:260539

TI Apparatus and method for flow electroporation of biological samples

IN Dzekunov, Sergey M.; Lee, Hyung J.; Li, Linhong; Singh, Vininder; Liu, Linda; Holaday, John W.

PA USA

SO U.S. Pat. Appl. Publ., 59 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----------------------|------|----------|-----------------|----------|
| PI US 2003059945 | A1 | 20030327 | US 2002-80272 | 20020221 |
| PRAI US 2001-269867P | P | 20010221 | | |
| US 2001-269868P | P | 20010221 | | |

L11 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS

AN 2003:140661 CAPLUS

TI HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D

AU Cozzolino, Mario; Vidal, Marcos; Arcidiacono, Maria Vittoria; Tebas, Pablo; Yarasheski, Kevin E.; Dusso, Adriana S.

CS Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, 63110, USA

SO AIDS (London, United Kingdom) (2003), 17(4), 513-520

CODEN: AIDSET; ISSN: 0269-9370

PB Lippincott Williams & Wilkins

DT Journal

LA English

RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS

AN 2002:736060 CAPLUS

DN 137:242163

TI Method and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds

IN Burke, Thomas G.; Carter, Daniel C.

PA New Century Pharmaceuticals, USA

SO PCT Int. Appl., 41 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| PATENT NO. | | KIND | DATE | APPLICATION NO. | DATE |
|------------|-----------------|------|--|-----------------|----------|
| PI | WO 2002074246 | A2 | 20020926 | WO 2002-US8301 | 20020320 |
| | WO 2002074246 | A3 | 20030220 | | |
| | | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | |
| | | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | |
| | US 2002193318 | A1 | 20021219 | US 2002-101513 | 20020320 |
| PRAI | US 2001-276908P | P | 20010320 | | |

L11 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:696159 CAPLUS
 DN 137:246071
 TI Gene expression profiles relating to normal and osteoarthritic cartilage
 IN Liew, Choong-Chin; Marshall, Wayne E.; Zhang, Hongwei
 PA Chondrogene Inc., Can.
 SO PCT Int. Appl., 777 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

| PATENT NO. | | KIND | DATE | APPLICATION NO. | DATE |
|------------|-----------------|------|--|-----------------|----------|
| PI | WO 2002070737 | A2 | 20020912 | WO 2002-CA247 | 20020228 |
| | WO 2002070737 | C1 | 20021031 | | |
| | | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | |
| | | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | |
| PRAI | US 2001-271955P | P | 20010228 | | |
| | US 2001-275017P | P | 20010312 | | |
| | US 2001-305340P | P | 20010713 | | |

L11 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:572142 CAPLUS
 DN 137:257242
 TI Classification of Biologically Active Compounds by Median Partitioning
 AU Godden, Jeffrey W.; Xue, Ling; Bajorath, Juergen
 CS Bothell Research Center (AMRI-BRC), Department of Computer-Aided Drug Discovery, Albany Molecular Research Inc. (AMRI), Bothell, WA, 98011, USA
 SO Journal of Chemical Information and Computer Sciences (2002), 42(5), 1263-1269
 CODEN: JCISD8; ISSN: 0095-2338
 PB American Chemical Society
 DT Journal
 LA English
 RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2003 ACS

AN 2002:483014 CAPLUS
 DN 137:62274
 TI Preparation of potent macrophage activating factors derived from cloned
 vitamin D-binding protein and its domain and their
 therapeutic usage for cancer, HIV infection and osteopetrosis
 IN Yamamoto, Nobuto
 PA USA
 SO U.S., 24 pp., Cont.-in-part of U. S. 5,620,846.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 4

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|----------------|-----------------|----------|
| PI | US 6410269 | B1 | 20020625 | US 1996-618485 | 19960319 |
| | US 5620846 | A | 19970415 | US 1995-478121 | 19950607 |
| | CA 2223940 | AA | 19961219 | CA 1996-2223940 | 19960605 |
| | WO 9640903 | A1 | 19961219 | WO 1996-US8867 | 19960605 |
| | W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE,
ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT,
LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
SG, SI | | | | |
| | RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,
IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML | | | | |
| | AU 9662535 | A1 | 19961230 | AU 1996-62535 | 19960605 |
| | EP 837932 | A1 | 19980429 | EP 1996-921279 | 19960605 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI | | | | |
| | CN 1191567 | A | 19980826 | CN 1996-195808 | 19960605 |
| JP 11511962 | T2 | 19991019 | JP 1996-501337 | 19960605 | |
| BR 9609072 | A | 20001024 | BR 1996-9072 | 19960605 | |
| RU 2198218 | C2 | 20030210 | RU 1998-100240 | 19960605 | |
| US 5712104 | A | 19980127 | US 1997-779729 | 19970106 | |
| US 5776671 | A | 19980707 | US 1997-938553 | 19970926 | |
| NO 9705771 | A | 19980130 | NO 1997-5771 | 19971208 | |
| US 5985545 | A | 19991116 | US 1998-39159 | 19980313 | |
| US 5998132 | A | 19991207 | US 1999-245755 | 19990208 | |
| US 2002055140 | A1 | 20020509 | US 2001-826463 | 20010405 | |
| PRAI | US 1995-478121 | A2 | 19950607 | | |
| | US 1996-618485 | A | 19960319 | | |
| | WO 1996-US8867 | W | 19960605 | | |
| | US 1997-779729 | A2 | 19970106 | | |
| | US 1997-938553 | A1 | 19970926 | | |
| | US 1998-39159 | A1 | 19980313 | | |

RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:392665 CAPLUS
 DN 136:364891
 TI Protein and cDNA sequences of a novel human VDUP-1 like protein and
 therapeutical uses
 IN Mao, Yumin; Xie, Yi
 PA Shanghai Shengyuan Gene Development Co., Ltd., Peop. Rep. China
 SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 37 pp.
 CODEN: CNXXEV
 DT Patent
 LA Chinese
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|------------|------|----------|-----------------|----------|
| PI | CN 1318551 | A | 20011024 | CN 2000-106835 | 20000419 |

L11 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:242880 CAPLUS
 DN 136:395332
 TI Accurate partitioning of compounds belonging to diverse activity classes
 AU Xue, Ling; Bajorath, Juergen
 CS Bothell Research Center, Albany Molecular Research Inc. (AMRI), Bothell, WA, 98011, USA
 SO Journal of Chemical Information and Computer Sciences (2002), 42(3), 757-764
 CODEN: JCISD8; ISSN: 0095-2338
 PB American Chemical Society
 DT Journal
 LA English
 RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 14 OF 33 CAPLUS COPYRIGHT 2003 ACS
 AN 2001:921220 CAPLUS
 DN 136:384820
 TI Host genetic background at CCR5 chemokine receptor and **vitamin D** receptor loci and human immunodeficiency virus (**HIV**) type 1 disease progression among **HIV**-seropositive injection drug users
 AU Barber, Yolanda; Rubio, Carmen; Fernandez, Elvira; Rubio, Manuel; Fibla, Joan
 CS Departament de Ciencies Mediques Basiques, Lleida, Spain
 SO Journal of Infectious Diseases (2001), 184(10), 1279-1288
 CODEN: JIDIAQ; ISSN: 0022-1899
 PB University of Chicago Press
 DT Journal
 LA English
 RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 15 OF 33 CAPLUS COPYRIGHT 2003 ACS
 AN 2001:319953 CAPLUS
 DN 134:337390
 TI Synthetic ligand activated transcriptional regulator proteins and their therapeutic use
 IN Barbas, Carlos F.; Kadan, Michael; Beerli, Roger
 PA Novartis A.-G., Switz.; The Scripps Research Institute
 SO PCT Int. Appl., 218 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|--|----------|-----------------|----------|
| PI | WO 2001030843 | A1 | 20010503 | WO 2000-EP10430 | 20001023 |
| | WO 2001030843 | C2 | 20020919 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| | EP 1226168 | A1 | 20020731 | EP 2000-972849 | 20001023 |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL
 JP 2003512827 T2 20030408 JP 2001-533840 20001023
 PRAI US 1999-433042 A 19991025
 US 2000-586625 A 20000602
 WO 2000-EP10430 W 20001023

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 16 OF 33 CAPLUS COPYRIGHT 2003 ACS
 AN 2001:115113 CAPLUS
 DN 134:163204
 TI Synthesis of novel **vitamin D** analogues as pharmaceutical agents
 IN Bretting, Claus Aage Svensgaard
 PA Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktie, Den.
 SO PCT Int. Appl., 55 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------------|----------|-----------------|----------|
| PI | WO 2001010829 | A1 | 20010215 | WO 2000-DK389 | 20000711 |
| | W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | EP 1206448 | A1 | 20020522 | EP 2000-943703 | 20000711 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | |
| | JP 2003506435 | T2 | 20030218 | JP 2001-515296 | 20000711 |
| | US 6573255 | B1 | 20030603 | US 2002-48363 | 20020201 |
| PRAI | US 1999-147200P | P | 19990804 | | |
| | WO 2000-DK389 | W | 20000711 | | |
| OS | MARPAT | 134:163204 | | | |

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 17 OF 33 CAPLUS COPYRIGHT 2003 ACS
 AN 2001:6065 CAPLUS
 DN 134:37051
 TI Method for immune-system strengthening and development of a lipid transporter for anti-**HIV** and antibacterial gene therapy

IN Worm, Richard; Correa, Michel; Mavoungou, Donatien
 PA Can.
 SO Fr. Demande, 16 pp.

CODEN: FRXXBL
 DT Patent
 LA French

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--------------|------|----------|-----------------|----------|
| PI | FR 2792201 | A1 | 20001020 | FR 1999-4706 | 19990415 |
| | FR 2792201 | B1 | 20011102 | | |
| PRAI | FR 1999-4706 | | 19990415 | | |

L11 ANSWER 18 OF 33 CAPLUS COPYRIGHT 2003 ACS
AN 2000:668410 CAPLUS
DN 133:333809
TI Changes in calciotropic hormones and biochemical markers of bone metabolism in patients with human immunodeficiency virus infection
AU Teichmann, Joachim; Stephan, Eva; Discher, Thomas; Lange, Uwe; Federlin, Konrad; Stracke, Hilmar; Friese, Georg; Lohmeyer, Jürgen; Bretzel, Reinhard G.
CS Medizinische Klinik III und Poliklinik, Justus-Liebig-Universität Giessen, Giessen, 35385, Germany
SO Metabolism, Clinical and Experimental (2000), 49(9), 1134-1139
CODEN: METAAJ; ISSN: 0026-0495
PB W. B. Saunders Co.
DT Journal
LA English
RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 19 OF 33 CAPLUS COPYRIGHT 2003 ACS
AN 2000:178334 CAPLUS
DN 132:306569
TI Osteoclasts expressing the measles virus nucleocapsid gene display a pagetic phenotype
AU Kurihara, Noriyoshi; Reddy, Sakamuri V.; Menaa, Cheikh; Anderson, Dirk; Roodman, G. David
CS Department of Medicine/Hematology, University of Texas Health Science Center, San Antonio, TX, 78229, USA
SO Journal of Clinical Investigation (2000), 105(5), 607-614
CODEN: JCINAO; ISSN: 0021-9738
PB American Society for Clinical Investigation
DT Journal
LA English
RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 20 OF 33 CAPLUS COPYRIGHT 2003 ACS
AN 2000:161479 CAPLUS
DN 132:204016
TI Adenoviral vectors and inducible expression system for gene expression and therapy
IN Mehtali, Majid; Sorg-guss, Tania
PA Transgene S.A., Fr.
SO PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|--|------|----------|-----------------|----------|
| PI | WO 2000012741 | A2 | 20000309 | WO 1999-FR2051 | 19990827 |
| | WO 2000012741 | A3 | 20000504 | | |
| | W: AU, CA, JP, US | | | | |
| | RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| | FR 2782732 | A1 | 20000303 | FR 1998-10842 | 19980828 |
| | CA 2341775 | AA | 20000309 | CA 1999-2341775 | 19990827 |
| | AU 9954262 | A1 | 20000321 | AU 1999-54262 | 19990827 |
| | EP 1108051 | A2 | 20010620 | EP 1999-940240 | 19990827 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| | JP 2002523106 | T2 | 20020730 | JP 2000-567726 | 19990827 |

PRAI FR 1998-10842 A 19980828
WO 1999-FR2051 W 19990827

L11 ANSWER 21 OF 33 CAPLUS COPYRIGHT 2003 ACS
AN 1999:722888 CAPLUS
DN 131:332124
TI Arylhydrocarbon receptor ligand antagonists, and therapeutic use
IN Savouret, Jean-Francois; Casper, Robert-Frederic; Milgrom, Edwin
PA Institut National de la Sante et de la Recherche Medicale (INSERM), Fr.
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2

DT Patent

LA French

FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| PI WO 9956737 | A1 | 19991111 | WO 1999-FR1063 | 19990505 |
| W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| FR 2778337 | A1 | 19991112 | FR 1998-5673 | 19980505 |
| FR 2778337 | B1 | 20010831 | | |
| CA 2331364 | AA | 19991111 | CA 1999-2331364 | 19990505 |
| AU 9935282 | A1 | 19991123 | AU 1999-35282 | 19990505 |
| EP 1075256 | A1 | 20010214 | EP 1999-916992 | 19990505 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI | | | | |
| JP 2002513754 | T2 | 20020514 | JP 2000-546764 | 19990505 |
| PRAI FR 1998-5673 | A | 19980505 | | |
| WO 1999-FR1063 | W | 19990505 | | |

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 22 OF 33 CAPLUS COPYRIGHT 2003 ACS
AN 1999:108400 CAPLUS
DN 130:324249
TI Hypocalcemia in HIV infection and AIDS
AU Kuehn, E. W.; Anders, H. J.; Bogner, J. R.; Obermaier, J.; Goebel, F. D.;
Schlondorff, D.
CS Medizinische Poliklinik, Ludwig Maximilians University, Munchen, Germany
SO Journal of Internal Medicine (1999), 245(1), 69-73
CODEN: JINMEO; ISSN: 0954-6820
PB Blackwell Science Ltd.
DT Journal
LA English

RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2003 ACS
AN 1998:804189 CAPLUS
DN 130:47474
TI Use of vitamin D compounds to prevent transplant
rejection
IN Deluca, Hector F.; Cantorna, Margherita T.; Hullett, Debra A.; Sollinger,
Hans W.; Humpal-Winter, Jean; Hayes, Colleen E.
PA Wisconsin Alumni Research Foundation, USA

SO PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9855127 | A1 | 19981210 | WO 1998-US11558 | 19980604 |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | AU 9878172 | A1 | 19981221 | AU 1998-78172 | 19980604 |
| | EP 998290 | A1 | 20000510 | EP 1998-926299 | 19980604 |
| | R: CH, DE, DK, ES, FR, IT, LI, IE | | | | |
| | JP 2002510304 | T2 | 20020402 | JP 1999-502872 | 19980604 |
| PRAI | US 1997-870337 | A | 19970606 | | |
| | US 1997-870569 | A | 19970606 | | |
| | WO 1998-US11558 | W | 19980604 | | |
| OS | MARPAT 130:47474 | | | | |

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 24 OF 33 CAPLUS COPYRIGHT 2003 ACS

AN 1998:737133 CAPLUS

DN 130:94374

TI Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis

AU Haug, Charlotte J.; Aukrust, Pal; Haug, Egil; Morkrid, Lars; Muller, Fredrik; Froland, Stig S.

CS Section of Clinical Immunology and Infectious Diseases, Medical Department A, and Research Institute for Internal Medicine, The National Hospital-Rikshospitalet, University of Oslo, Oslo, N-0027, Norway

SO Journal of Clinical Endocrinology and Metabolism (1998), 83(11), 3832-3838
CODEN: JCEMAZ; ISSN: 0021-972X

PB Endocrine Society

DT Journal

LA English

RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 25 OF 33 CAPLUS COPYRIGHT 2003 ACS

AN 1998:661494 CAPLUS

DN 129:298375

TI Antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases

IN Squires, Meryl

PA USA

SO PCT Int. Appl., 99 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|--|------|----------|-----------------|----------|
| PI | WO 9842188 | A1 | 19981001 | WO 1998-US5792 | 19980324 |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, | | | | |

DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG,
 KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
 NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
 UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,
 FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
 GA, GN, ML, MR, NE, SN, TD, TG
 US 6350784 B1 20020226 US 1997-824041 19970326
 AU 9867718 A1 19981020 AU 1998-67718 19980324
 AU 727339 B2 20001207
 BR 9807892 A 20000222 BR 1998-7892 19980324
 EP 980203 A1 20000223 EP 1998-913086 19980324
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 EE 9900436 A 20000417 EE 1999-436 19980324
 NZ 500002 A 20010928 NZ 1998-500002 19980324
 JP 2001527541 T2 20011225 JP 1998-545926 19980324
 NO 9904639 A 19991124 NO 1999-4639 19990924
 MX 9908750 A 20000331 MX 1999-8750 19990924
 BG 63612 B1 20020731 BG 1999-103786 19991007
 PRAI US 1997-824041 A 19970326
 US 1996-600217 A2 19960212
 US 1996-646988 A2 19960508
 WO 1998-US5792 W 19980324

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 26 OF 33 CAPLUS COPYRIGHT 2003 ACS
 AN 1998:478450 CAPLUS
 DN 129:326467
 TI Different effect of 1,25-dihydroxyvitamin D3 on replication of
 Mycobacterium avium in monocyte-derived macrophages from human
 immunodeficiency virus-infected subjects and healthy controls
 AU Haug, Charlotte J.; Muller, Fredrik; Aukrust, Pal; Froland, Stig S.
 CS Medical Department A, Institute for Internal Medicine, Section of Clinical
 Immunology and Infectious Diseases and Research, The National
 Hospital-Rikshospitalet, University of Oslo, Oslo, N-0027, Norway
 SO Immunology Letters (1998), 63(2), 107-112
 CODEN: IMLED6; ISSN: 0165-2478
 PB Elsevier Science B.V.
 DT Journal
 LA English

RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 27 OF 33 CAPLUS COPYRIGHT 2003 ACS
 AN 1998:279452 CAPLUS
 DN 129:26703
 TI The immunogenetics of human infectious diseases
 AU Hill, Adrian V. S.
 CS Wellcome Trust Cent. Human Genetics, Univ. Oxford, Oxford, OX3 7BN, UK
 SO Annual Review of Immunology (1998), 16, 593-617
 CODEN: ARIMDU; ISSN: 0732-0582
 PB Annual Reviews Inc.
 DT Journal; General Review
 LA English

RE.CNT 128 THERE ARE 128 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 28 OF 33 CAPLUS COPYRIGHT 2003 ACS
 AN 1998:124001 CAPLUS
 DN 128:196677

TI Spontaneously dispersible concentrates of sterol esters and
 vitamin D derivatives with antiviral and/or
 parasiticidal effects
 IN Eugster, Carl
 PA Marigen S.A., Switz.; Eugster, Carl
 SO PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| PI WO 9806390 | A1 | 19980219 | WO 1996-CH280 | 19960813 |
| W: US | | | | |
| RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| EP 858331 | A1 | 19980819 | EP 1996-925634 | 19960813 |
| R: DE, FR, GB, IT | | | | |
| PRAI WO 1996-CH280 | | 19960813 | | |
| OS MARPAT 128:196677 | | | | |
| RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD | | | | |
| ALL CITATIONS AVAILABLE IN THE RE FORMAT | | | | |

L11 ANSWER 29 OF 33 CAPLUS COPYRIGHT 2003 ACS
 AN 1997:757910 CAPLUS
 DN 128:73688
 TI Changes in 1,25-(OH)2D3 synthesis and its receptor expression in spleen
 cell subpopulations of mice infected with LPBM5 retrovirus
 AU Nguyen, T. M.; Pavlovitch, J.; Papiernik, M.; Guillozo, H.;
 Walrant-Debray, O.; Pontoux, C.; Garabedian, M.
 CS CNRS, URA 583, Hopital Saint-Vincent de Paul, Univ. Paris V, Paris, 75014,
 Fr.
 SO Endocrinology (1997), 138(12), 5505-5510
 CODEN: ENDOAO; ISSN: 0013-7227
 PB Endocrine Society
 DT Journal
 LA English

L11 ANSWER 30 OF 33 CAPLUS COPYRIGHT 2003 ACS
 AN 1997:618212 CAPLUS
 DN 127:261305
 TI A TaqI RFLP in the **vitamin D** receptor gene and its
 association with susceptibility to infectious disease with an autoimmune
 component
 IN Hill, Adrian; Bellamy, Richard; Ruwende, Cyril; Whittle, Hilton; Roy,
 Suchismita; Thursz, Mark; Ali, Suleman
 PA Isis Innovation Ltd., UK; Hill, Adrian; Bellamy, Richard; Ruwende, Cyril;
 Whittle, Hilton; Roy, Suchismita; Thursz, Mark; Ali, Suleman
 SO PCT Int. Appl., 66 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| PI WO 9732998 | A2 | 19970912 | WO 1997-GB637 | 19970310 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,
PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ,
VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB,
GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, | | | | |

ML, MR, NE, SN, TD, TG
 AU 9721019 A1 19970922 AU 1997-21019 19970310
 WO 9833938 A1 19980806 WO 1998-GB300 19980130
 W: JP, US
 RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
 PRAI GB 1996-4985 19960308
 GB 1996-21866 19961021
 GB 1997-1919 19970130
 WO 1997-GB637 19970310

L11 ANSWER 31 OF 33 CAPLUS COPYRIGHT 2003 ACS
 AN 1997:116550 CAPLUS
 DN 126:113175
 TI Macrophage-activating factors derived from cloned vitamin D3-binding protein, therapeutic uses, and N-acetylgalactosaminidase detection in disease diagnosis

IN Yamamoto, Nobuto
 PA Yamamoto, Nobuto, USA
 SO PCT Int. Appl., 42 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 4

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9640903 | A1 | 19961219 | WO 1996-US8867 | 19960605 |
| | W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI | | | | |
| | RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML | | | | |
| | US 5620846 | A | 19970415 | US 1995-478121 | 19950607 |
| | US 6410269 | B1 | 20020625 | US 1996-618485 | 19960319 |
| | AU 9662535 | A1 | 19961230 | AU 1996-62535 | 19960605 |
| | EP 837932 | A1 | 19980429 | EP 1996-921279 | 19960605 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| | JP 11511962 | T2 | 19991019 | JP 1996-501337 | 19960605 |
| | BR 9609072 | A | 20001024 | BR 1996-9072 | 19960605 |
| | RU 2198218 | C2 | 20030210 | RU 1998-100240 | 19960605 |
| | NO 9705771 | A | 19980130 | NO 1997-5771 | 19971208 |
| PRAI | US 1995-478121 | A | 19950607 | | |
| | US 1996-618485 | A | 19960319 | | |
| | WO 1996-US8867 | W | 19960605 | | |

L11 ANSWER 32 OF 33 CAPLUS COPYRIGHT 2003 ACS
 AN 1996:682599 CAPLUS
 DN 126:153113
 TI The effect of 1,25-vitamin D3 on maturation of monocytes from **HIV**-infected patients varies with degree of immunodeficiency
 AU Haug, C. J.; Mueller, F.; Rollag, H.; Aukrust, P.; Degre, M.; Froeland, S.
 CS Kaptein W. Wilhelmsen og Frues Inst. Bacteriol., Univ. Oslo, Oslo, N-0027, Norway
 SO APMIS (1996), 104(7-8), 539-548
 CODEN: APMSEL; ISSN: 0903-4641
 PB Munksgaard
 DT Journal
 LA English

L11 ANSWER 33 OF 33 CAPLUS COPYRIGHT 2003 ACS

AN 1991:22763 CAPLUS
DN 114:22763
TI Toxic levels of dietary supplementation in **HIV-1** infected patients
AU Fordyce-Baum, M. K.; Mantero-Atienza, E.; Morgan, R.; Van Riel, F.; Beach, R. S.
CS Sch. Med., Univ. Miami, Miami, FL, USA
SO Archives of AIDS Research (1990), 4(1-2), 149-57
CODEN: AARSE9; ISSN: 0899-4811
DT Journal
LA English

=> d 111 32 all

L11 ANSWER 32 OF 33 CAPLUS COPYRIGHT 2003 ACS
AN 1996:682599 CAPLUS
DN 126:153113
TI The effect of 1,25-vitamin D3 on maturation of monocytes from **HIV**-infected patients varies with degree of immunodeficiency
AU Haug, C. J.; Mueller, F.; Rollag, H.; Aukrust, P.; Degre, M.; Froeland, S. S.
CS Kaptein W. Wilhelmsen og Frues Inst. Bacteriol., Univ. Oslo, Oslo, N-0027, Norway
SO APMIS (1996), 104(7-8), 539-548
CODEN: APMSEL; ISSN: 0903-4641
PB Munksgaard
DT Journal
LA English
CC 2-10 (Mammalian Hormones)
AB The active metabolite of **vitamin D**, 1,25-dihydroxyvitamin D3 (1,25D), has been shown to induce monocyte-to-macrophage maturation in vitro as well as monocytic differentiation of bone marrow precursors and monocytic leukemic cell lines. In this study the authors assessed whether 1,25D could improve the maturation defect the authors have previously demonstrated in monocytes from AIDS patients. In vitro growth and maturation of monocytes from 10 controls, 15 asymptomatic **HIV** pos. (CDC group II or III) and 13 symptomatic **HIV** pos. (CDC group IV) was examd. by assessing cellular morphol., differentiation, adherence and protein content. Cells were cultured for 10 days with or without addn. of 1,25D at a concn. of 100 pg/mL. In addn., patients were monitored clin. and by immunol. parameters and **HIV** p24 antigen in serum. The present study showed that addn. of 1,25D significantly improved the growth and maturation in both patient and control groups. There was a significant neg. correlation between response to 1,25D and CD4+ lymphocyte count in blood in **HIV**-infected patients. A greater response to 1,25D was seen in monocytes from patients with advanced immunodeficiency and symptomatic disease than in monocytes from asymptomatic patients. However, in the most advanced cases of **HIV** infection with serious ongoing opportunistic infections the response to 1,25D was very poor, possibly reflecting profound and incorrigible dysfunction of monocytes.
ST dihydroxyvitamin D3 monocyte macrophage HIV1 AIDS
IT AIDS (disease)
Human immunodeficiency virus 1
Immunodeficiency
Macrophage
Monocyte
(effect of 1,25-vitamin D3 on maturation of monocytes from **HIV**-infected humans varies with degree of immunodeficiency)
IT 32222-06-3, Ro 21-5535

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(effect of 1,25-vitamin D3 on maturation of monocytes from **HIV**-infected humans varies with degree of immunodeficiency)

=> d 111 28 all

L11 ANSWER 28 OF 33 CAPLUS COPYRIGHT 2003 ACS
AN 1998:124001 CAPLUS

DN 128:196677

TI Spontaneously dispersible concentrates of sterol esters and **vitamin D** derivatives with antiviral and/or parasiticidal effects

IN Eugster, Carl

PA Marigen S.A., Switz.; Eugster, Carl

SO PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DT Patent

LA German

IC ICM A61K031-215

ICS A61K031-575; A61K031-59

CC 63-6 (Pharmaceuticals)

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|--|------|----------|-----------------|----------|
| PI | WO 9806390 | A1 | 19980219 | WO 1996-CH280 | 19960813 |
| | W: US | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| | EP 858331 | A1 | 19980819 | EP 1996-925634 | 19960813 |
| | R: DE, FR, GB, IT | | | | |

PRAI WO 1996-CH280 19960813

OS MARPAT 128:196677

AB Ultramicroemulsions prep'd. from spontaneously dispersible concs. of C2-31 alkyl, C3-31 alkenyl or alkapolyyenyl, and retinyl esters of certain sterols and **vitamin D** derivs., together with surfactants and optional solvents, emulsifiers, and coemulsifiers, show antiviral/virucidal and/or parasiticidal (esp. trypanosomicidal) activity. The micellar structure of these esters in the inner oil phase of the emulsions allows them to diffuse through cell membranes into infected cells. Thus, 44 wt.% granules contg. Metolose 90 SH-4000 90.0, Avicel PH-101 80.3, Marigenol conc. (contg. β -sitosteryl palmitate) 134.9, and Aerosil 200 80.3 parts were coated with a mixt. of Marigenol conc. 25 and Aqoat AS-HG enteric delayed-release coating material 31 parts to produce a multiple-unit prepn. An ultramicroemulsion contg. 100 ppm β -sitosteryl palmitate protected MT4 cells (an eternalized T-cell line) from infection with **HIV** IIIB.

ST virucide sterol **vitamin D** ester; parasiticide sterol **vitamin D** ester; microemulsion sterol **vitamin D** ester

IT Polyoxyalkylenes, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkylphenyl group-terminated, phosphate esters; spontaneously dispersible concs. of sterol esters and **vitamin D** derivs. with antiviral and parasiticidal effects)

IT Sterols

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(esters; spontaneously dispersible concs. of sterol esters and **vitamin D** derivs. with antiviral and parasiticidal

effects)

IT Terpenes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxy, esters; spontaneously dispersible concs. of sterol esters and
vitamin D derivs. with antiviral and parasiticidal
effects)

IT Protozoacides
(leishmanicides; spontaneously dispersible concs. of sterol esters and
vitamin D derivs. with antiviral and parasiticidal
effects)

IT Drug delivery systems
(microemulsions; spontaneously dispersible concs. of sterol esters and
vitamin D derivs. with antiviral and parasiticidal
effects)

IT Antiviral agents
Emulsifying agents
Feline immunodeficiency virus
Hepatitis B virus
Human herpesvirus
Human herpesvirus 5
Human immunodeficiency virus 1
Parasiticides
Trypanosomicides
(spontaneously dispersible concs. of sterol esters and **vitamin D** derivs. with antiviral and parasiticidal effects)

IT Alcohols, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(terpenoid, esters; spontaneously dispersible concs. of sterol esters and
vitamin D derivs. with antiviral and
parasiticidal effects)

IT 601-34-3, Cholesteryl palmitate 1406-16-2D, **Vitamin D**
, derivs., esters 1908-11-8, Cholesteryl laurate 2308-84-1,
Stigmasteryl palmitate 2308-85-2, .beta.-Sitosteryl palmitate
2573-03-7, Cholesteryl arachidate 3177-92-2 3712-16-1,
.beta.-Sitosteryl oleate 3992-98-1, Ergosteryl palmitate 7726-03-6,
Cholesteryl valerate 13403-09-3 13403-10-6 20242-97-1, Stigmasteryl
laurate 22554-56-9 29398-23-0 33249-10-4 34137-25-2,
.beta.-Sitosteryl stearate 39793-25-4 41005-65-6, .beta.-Sitosteryl
laurate 41328-97-6, Cholesteryl isovalerate 58380-68-0 59000-65-6
59015-74-6, .beta.-Sitosteryl arachidate 61192-68-5 80589-29-3
110026-12-5, Cholestanyl 10-undecenoate 122295-96-9 144338-30-7
144338-31-8 144338-42-1 144951-98-4 144951-99-5 146513-01-1
146513-03-3 146513-04-4 146513-07-7 153023-84-8 158180-12-2
203392-49-8 203392-50-1 203392-51-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(spontaneously dispersible concs. of sterol esters and **vitamin D** derivs. with antiviral and parasiticidal effects)

IT 106-22-9D, Citronellol, esters with aliph. acids 106-24-1D, Geranyl
alcohol, esters with aliph. acids 110-27-0, Isopropyl myristate
142-91-6, Isopropyl palmitate 150-86-7D, esters with aliph. acids
505-32-8D, esters with aliph. acids 4602-84-0D, Farnesol, esters with
aliph. acids 6032-29-7, 2-Pentanol 7365-45-9, HEPES 9005-64-5,
Polyoxyethylenesorbitan monolaurate 9036-19-5 68389-70-8 75621-03-3,
CHAPS 105362-40-1, Soprophor FL
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(spontaneously dispersible concs. of sterol esters and **vitamin D** derivs. with antiviral and parasiticidal effects)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Ikeda, S; ANTIVIRAL CHEM CHEMOTHER 1994, V5(2), P122 CAPLUS

(2) Marigen S A Riehen; WO 9221670 A 1992 CAPLUS
 (3) Marigen Sa; WO 9101139 A 1991 CAPLUS
 (4) Marigen Sa; WO 9212989 A 1992 CAPLUS

=> d 111 25 all

L11 ANSWER 25 OF 33 CAPLUS COPYRIGHT 2003 ACS
 AN 1998:661494 CAPLUS
 DN 129:298375
 TI Antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases
 IN Squires, Meryl
 PA USA
 SO PCT Int. Appl., 99 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A01N033-12
 ICS A61K031-14
 CC 1-5 (Pharmacology)
 Section cross-reference(s): 63

FAN.CNT 5

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9842188 | A1 | 19981001 | WO 1998-US5792 | 19980324 |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | US 6350784 | B1 | 20020226 | US 1997-824041 | 19970326 |
| | AU 9867718 | A1 | 19981020 | AU 1998-67718 | 19980324 |
| | AU 727339 | B2 | 20001207 | | |
| | BR 9807892 | A | 20000222 | BR 1998-7892 | 19980324 |
| | EP 980203 | A1 | 20000223 | EP 1998-913086 | 19980324 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | EE 9900436 | A | 20000417 | EE 1999-436 | 19980324 |
| | NZ 500002 | A | 20010928 | NZ 1998-500002 | 19980324 |
| | JP 2001527541 | T2 | 20011225 | JP 1998-545926 | 19980324 |
| | NO 9904639 | A | 19991124 | NO 1999-4639 | 19990924 |
| | MX 9908750 | A | 20000331 | MX 1999-8750 | 19990924 |
| | BG 63612 | B1 | 20020731 | BG 1999-103786 | 19991007 |
| PRAI | US 1997-824041 | A | 19970326 | | |
| | US 1996-600217 | A2 | 19960212 | | |
| | US 1996-646988 | A2 | 19960508 | | |
| | WO 1998-US5792 | W | 19980324 | | |

AB An improved medical treatment and medicine is provided to quickly and safely resolve **HIV** and other microbial infections. The inexpensive medicine can be self administered and maintained for the prescribed time. The attractive medicine comprises an antimicrobial conc. comprising microbe inhibitors, phytochems. or isolates. Desirably, the effective medicine comprises a surfactant and an aq. carrier or solvent and a nutrient. In the preferred form, the medicine comprises: Echinacea and Commiphora myrrha phytochems., benzalkonium chloride, a sterile water soln., and folic acid.

ST phytochem nutrient antimicrobial **HIV**; Echinacea Commiphora phytochem surfactant antimicrobial **HIV**; folic acid phytochem

IT antimicrobial **HIV**
Labia
Lip
Lymph node
Lymphatic system
T cell (lymphocyte)
(administration to; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkylbenzyldimethyl, bromides; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkylbenzyldimethyl, chlorides; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Surfactants
(amphoteric; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Bacilli
(anaerobic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Allium
Anise
Arctostaphylos
Artemisia
Baptisia
Calendula
Capsicum
Carum
Compositae (Asteraceae)
Coriandrum
Echinacea angustifolia
Echinacea atrabactilus
Echinacea pallida
Echinacea purpurea
Echinacea vegetalis
Eucalyptus
Eugenia mytacea
Gentian (Gentiana)
Inula
Juniper (Juniperus)
Labiatae (Lamiaceae)
Meliosma
Mentha
Mentha aquatica hypeuria
Myroxylon
Origanum
Parthenium integrifolium
Plantago
Rosemary
Ruta
Sage (Salvia)
(antimicrobial isolates of; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Adenoviridae
Antibacterial agents
Antimicrobial agents
Antiviral agents
Arbovirus
Arenavirus
Bird (Aves)

Cat (*Felis catus*)
Cattle
Commiphora erythraea
Commiphora molmol
Commiphora myrrha
Coronavirus
Cytomegalovirus
Dog (*Canis familiaris*)
Drug delivery systems
Gums and Mucilages
Horse (*Equus caballus*)
Human herpesvirus 1
Human herpesvirus 2
Human herpesvirus 3
Human herpesvirus 4
Human immunodeficiency virus
Human parainfluenza virus
Influenza virus
Livestock
Mycobacterium
Nutrients
Papillomavirus
Picornaviridae
Rodent
Sexually transmitted diseases
Sheep
Staphylococcus
Streptococcus
Surfactants
Swine
(antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)
IT Amides, biological studies
Anthocyanins
Enzymes, biological studies
Natural products, pharmaceutical
Polyacetylenes, biological studies
Polysaccharides, biological studies
Proteins, general, biological studies
Sesquiterpenes
Tannins
Vitamins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)
IT Encephalitis
Meningitis
(bacterial and viral; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)
IT Detergents
Surfactants
(cationic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)
IT Inflammation
(cellulitis; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)
IT Polyacetylenes, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(derivs.; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Vitamins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fat-sol.; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(injections; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Mouth
(mucosa, administration to; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(nasal; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Surfactants
(nonionic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(ophthalmic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Animal tissue
(periacinal, administration to; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Plant (Embryophyta)
(phytochems.; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Intestine
(rectum, anus, administration to; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(sublingual; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(surfactant; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Carboxylic acids, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetraenoic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(topical, and systemic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(vaginal; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Vitamins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(water-sol.; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Surfactants
(zwitterionic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT 50-81-7, Ascorbic acid, biological studies 57-10-3, Hexadecanoic acid,

biological studies 57-88-5, Cholesterol, biological studies 58-86-6, Xylose, biological studies 59-23-4, Galactose, biological studies 59-30-3, Folic acid, biological studies 59-43-8, Thiamin, biological studies 59-67-6, Niacin, biological studies 64-19-7, Acetic acid, biological studies 68-19-9, Vitamin B12 76-49-3, Bornyl acetate 79-83-4, Vitamin B5 80-56-8, .alpha.-Pinene 83-46-5, .beta.-Sitosterol 83-48-7, Stigmasterol 83-88-5, Riboflavin, biological studies 87-44-5, Caryophyllene 87-69-4, biological studies 97-53-0, Eugenol 104-55-2, Cinnamaldehyde 108-39-4, biological studies 112-85-6D, Docosanoic acid, derivs. 117-39-5, Quercetin 121-33-5, Vanillin 122-03-2, Cuminaldehyde 127-91-3, .beta.-Pinene 138-86-3, Limonene 147-81-9, Arabinose 153-18-4, Rutin 327-97-9, Chlorogenic acid 331-39-5, Caffeic acid 331-39-5D, Caffeic acid, esters 474-58-8 474-62-4, Campesterol 480-10-4, Kaempferol-3-glucoside 482-35-9, Quercetin-3-glucoside 482-36-0 491-70-3, Luteolin 495-62-5, .gamma.-Bisabolene 504-97-2, Echinacein 507-70-0, Borneol 520-18-3, Kaempferol 520-36-5, Apigenin 534-61-2, Isochlorogenic acid 536-60-7, Cumaric alcohol 548-75-4, Quercetagetin-7-glucoside 563-83-7 593-50-0, n-Triacontanol 604-80-8 638-96-0, .alpha.-Amyrone 639-99-6, Elemol 643-20-9D, Pyrrolizidine, alkaloid 1139-30-6, Caryophyllene epoxide 1406-16-2, **Vitamin D** 1406-18-4, Vitamin E 2450-53-5, 3,5-Dicaffeoylquinic acid 3562-36-5, Pontica epoxide 3615-41-6, Rhamnose 3812-32-6, Carbonate, biological studies 3943-97-3, Methyl p-hydroxycinnamate 4120-73-4, 4-O-Methylglucuronic acid 5373-11-5, Luteolin-7-glucoside 5937-48-4, 3-epi-.alpha.-Amyrin 6537-80-0, Chicoric acid 6556-12-3, Glucuronic acid 7235-40-7, .beta.-Carotene 7439-89-6, Iron, biological studies 7439-95-4, Magnesium, biological studies 7439-96-5, Manganese, biological studies 7440-09-7, Potassium, biological studies 7440-23-5, Sodium, biological studies 7440-48-4, Cobalt, biological studies 7440-70-2, Calcium, biological studies 7723-14-0, Phosphorus, biological studies 7782-49-2, Selenium, biological studies 8001-18-1, Echinacin 8059-24-3, Vitamin B6 9005-80-5, Inulin 9014-63-5D, Xylan, derivs. 9036-66-2, Arabinogalactan 9040-28-2, 4-O-Methylglucuronoarabinoxylan 11006-56-7, Vitamin B15 11103-57-4, Vitamin A 12001-79-5, Vitamin K 12627-13-3, Silicate 13360-61-7, 1-Pentadecene 14808-79-8, Sulfate, biological studies 16887-00-6, Chloride, biological studies 17627-44-0, .alpha.-Bisabolene 17650-84-9 18668-90-1, 8-Pentadecen-2-one 18794-84-8, .beta.-Farnesene 19912-61-9, Furanodiene 20493-56-5, Curzerenone 23986-74-5, Germacrene D 24268-41-5, Furanodienone 24738-51-0 25067-58-7, Polyacetylene 25067-58-7D, Polyacetylene, derivs. 27214-55-7, Quercetin-3-xyloside 28028-64-0, Germacrene 29350-73-0, Cadinene 30964-13-7, Cynarin 36129-21-2 39007-92-6, Commiferin 47705-70-4 52525-35-6 57378-72-0 59440-97-0, Echinolone 61276-17-3, Verbascoside 67879-58-7 69350-61-4, Epishybunol 74282-22-7 75081-19-5, Pentadecadiene 76963-26-3 80151-77-5, Tussilagine 82854-37-3, Echinacoside 84744-28-5 91108-32-6, Isotussilagine 94977-38-5 99119-75-2 99119-76-3 116752-09-1 116752-10-4 117841-81-3 118853-85-3 125199-93-1 148879-89-4, Commiphorinic acid 149531-55-5, .alpha.-Commiphoric acid 149531-56-6, .beta.-Commiphoric acid 149531-57-7, .gamma.-Commiphoric acid 162666-19-5, Inuloidin 205510-62-9, Echinacin B 214041-69-7 214041-70-0 214041-71-1 214041-72-2 214041-73-3 214405-10-4, Heerabolene 214405-11-5, .alpha.-Heerabomyrrhol 214405-12-6, .beta.-Heerabomyrrhol 214405-13-7, Heeraboresene 214405-44-4, Viracea 1 214405-45-5, Viracea 2 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT 120-32-1, o-Benzyl-p-chlorophenol 139-07-1, Lauryldimethylbenzylammonium

chloride 5538-94-3, Dioctyldimethylammonium chloride 7173-51-5,
Didecyldimethylammonium chloride 32426-11-2, Octyldecyldimethylammonium
chloride

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antimicrobial prevention and treatment of human immunodeficiency virus
and other infectious diseases)

IT 12001-76-2, Vitamin B

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)

(complex; antimicrobial prevention and treatment of human
immunodeficiency virus and other infectious diseases)

IT 79-14-1D, Glycolic acid, derivs.

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(surfactant; antimicrobial prevention and treatment of human
immunodeficiency virus and other infectious diseases)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Bryant; US 4797420 A 1989 CAPLUS
- (2) Hempel; DE 3521143 A1 CAPLUS Acc No 1987:483909 1986 CAPLUS
- (3) Silverman; US 5455033 A 1995
- (4) Tyle, R; "The Honest Herbal, A Sensible Guide to the Use of Herbs and
Related Remedies", 3rd Edition 1993, P115
- (5) Tyler, V; Herbs of choice, The Therapeutic Use of Phytomedicinals 1994,
P181
- (6) Wainberg; Arch AIDS Res, CAPLUS Acc No 1988:147004 1987, V1(1), P57 CAPLUS

=> d 111 22 all

L11 ANSWER 22 OF 33 CAPLUS COPYRIGHT 2003 ACS

AN 1999:108400 CAPLUS

DN 130:324249

TI Hypocalcemia in **HIV** infection and AIDS

AU Kuehn, E. W.; Anders, H. J.; Bogner, J. R.; Obermaier, J.; Goebel, F. D.;
Schlondorff, D.

CS Medizinische Poliklinik, Ludwig Maximilians University, Munchen, Germany

SO Journal of Internal Medicine (1999), 245(1), 69-73

CODEN: JINMEO; ISSN: 0954-6820

PB Blackwell Science Ltd.

DT Journal

LA English

CC 15-8 (Immunochemistry)

AB The objective here was to study the prevalence and possible mechanisms of
hypocalcemia in **HIV** infection and AIDS in 828 patients with
HIV infection or AIDS and 549 controls. Measured were total serum
calcium and albumin levels. Parameters of calcium homeostasis were detd.
in a subgroup of 21 hypocalcemic AIDS patients. Mean serum calcium was
2.34 mmol L-1 in the **HIV** group vs. 2.46 mmol L-1 in controls.

After adjusting for serum albumin, hypocalcemia was present in 6.5% of the
HIV group vs. 1.1% of controls. Mean serum calcium was declining
according to CDC groups, and differed from controls in each group.

Regression coeffs. of calcium vs. albumin were 0.147 amongst **HIV**
-infected patients and 0.106 for controls. In the subgroup of
hypocalcemic patients with AIDS, 10/21 had **vitamin D**

deficiency, 6 of these with low ionized calcium levels. Low serum PTH was
found in 2/21 patients, magnesium deficiency in 1/21. Of the remaining 8
patients, only 1 had secondary hyperparathyroidism, while the other 7
lacked an adequate PTH response, despite low ionized calcium levels in 4
subjects. Mean serum calcium concns. were lower through all CDC stages,
irresp. of albumin, resulting in a higher prevalence of hypocalcemia in
HIV-pos. patients compared with controls. In a considerable no.,

this seems to be caused by **vitamin D** deficiency and potentially a lack of adequate PTH secretion.
 ST hypocalcemia **HIV** infection AIDS
 IT AIDS (disease)
 Human immunodeficiency virus 1
 Hypoparathyroidism
 (hypocalcemia in **HIV** infection and AIDS in relation to **vitamin D** deficiency and PTH secretion)
 IT 1406-16-2, **Vitamin D** 7439-95-4, Magnesium, biological studies
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study) (deficiency; hypocalcemia in **HIV** infection and AIDS in relation to **vitamin D** deficiency and PTH secretion)
 IT 7440-70-2, Calcium, biological studies
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study) (hypocalcemia in **HIV** infection and AIDS in relation to **vitamin D** deficiency and PTH secretion)
 IT 9002-64-6, Parathyroid hormone
 RL: BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)
 (hypocalcemia in **HIV** infection and AIDS in relation to **vitamin D** deficiency and PTH secretion)
 IT 7440-70-2, Calcium, biological studies
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study) (hypocalcemia; hypocalcemia in **HIV** infection and AIDS in relation to **vitamin D** deficiency and PTH secretion)

RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Brezis, M; Miner Electrolyte Metab 1982, V8, P307 MEDLINE
- (2) Brown, L; Endocrinol Metab Clin North Am 1991, V20, P655
- (3) Coodley, G; AIDS 1993, V7, P1595 MEDLINE
- (4) Coodley, G; J Acquir Immune Defic Syndr 1994, V7, P681 MEDLINE
- (5) Croxson, T; J Clin Endocrinol Metab 1989, V68, P317 MEDLINE
- (6) Desai, T; Am J Med 1988, V84, P209 MEDLINE
- (7) Dobs, A; Am J Med 1988, V84, P611 MEDLINE
- (8) Freedman, D; Br Med J 1982, V284, P700 MEDLINE
- (9) Glassoc, R; Ann Intern Med 1992, V112, P35
- (10) Grinspoon, S; N Engl J Med 1992, V327, P1360 CAPLUS
- (11) Haug, C; J Infect Dis 1994, V169, P889 MEDLINE
- (12) Hellman, P; AIDS Res Hum Retroviruses 1994, V10, P391 MEDLINE
- (13) Hellman, P; Surgery 1996, V120, P985 MEDLINE
- (14) Horwitz, C; Am J Med 1972, V52, P797 MEDLINE
- (15) Jacobsen, M; J Clin Endocrinol Metab 1991, V72, P1130
- (16) Jaeger, P; J Clin Endocrinol Metab 1994, V79, P1701 CAPLUS
- (17) Lebowitz, M; Semin Nephrol 1992, V12, P146 MEDLINE
- (18) Lecatasa, G; Proc Soc Exp Biol Med 1984, V178, P653
- (19) Lehmann, R; Horm Res 1994, V42, P295 CAPLUS
- (20) Li, Y; J Clin Invest 1996, V97, P889
- (21) Macher, A; N Engl J Med 1983, V309, P1454 MEDLINE
- (22) Membreño, L; J Clin Endocrinol Metab 1987, V65, P482 MEDLINE
- (23) Neufeld, M; Medicine 1981, V60, P355 MEDLINE
- (24) Payne, R; Br Med J 1973, V4, P643 MEDLINE
- (25) Perazella, M; J Gen Intern Med 1994, V9, P232 MEDLINE
- (26) Peter, S; J Natl Med Assoc 1991, V83, P889 MEDLINE
- (27) Peter, S; J Natl Med Assoc 1992, V84, P626 MEDLINE
- (28) Poretzky, L; Mt Sinai J Med 1990, V57, P236 MEDLINE
- (29) Raffi, F; AIDS 1991, V5, P729 MEDLINE
- (30) Stein, T; Metabolism 1990, V39, P876 MEDLINE
- (31) Strauss, K; Arch Intern Med 1991, V151, P1441 MEDLINE
- (32) Welch, K; JAMA 1984, V252, P1152 MEDLINE
- (33) Zaloga, G; Ann Intern Med 1987, V107, P36 MEDLINE

(34) Zaloga, G; Crit Care Med 1992, V20, P251 MEDLINE

=> d his

(FILE 'HOME' ENTERED AT 15:19:02 ON 07 JUL 2003)

FILE 'REGISTRY' ENTERED AT 15:19:14 ON 07 JUL 2003

L1 101 S PANTOTHENIC ACID
L2 2 S VITAMIN B5
L3 2 S VITAMIN B3
L4 1 S L2 NOT L3

FILE 'CAPLUS' ENTERED AT 15:20:40 ON 07 JUL 2003

L5 5882 S L1
E RETROVIRAL
L6 13948 S E1-E6
L7 50063 S HIV
L8 61642 S L7 OR L6
L9 8 S L5 AND L8
L10 21260 S VITAMIN D
L11 33 S L10 AND L8

=> d his

(FILE 'HOME' ENTERED AT 15:19:02 ON 07 JUL 2003)

FILE 'REGISTRY' ENTERED AT 15:19:14 ON 07 JUL 2003

L1 101 S PANTOTHENIC ACID
L2 2 S VITAMIN B5
L3 2 S VITAMIN B3
L4 1 S L2 NOT L3

FILE 'CAPLUS' ENTERED AT 15:20:40 ON 07 JUL 2003

L5 5882 S L1
E RETROVIRAL
L6 13948 S E1-E6
L7 50063 S HIV
L8 61642 S L7 OR L6
L9 8 S L5 AND L8
L10 21260 S VITAMIN D
L11 33 S L10 AND L8

=> d 19 6-8

L9 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2003 ACS

AN 1998:661494 CAPLUS

DN 129:298375

TI Antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases

IN Squires, Meryl

PA USA

SO PCT Int. Appl., 99 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|------|-----------------|------|
|------------|------|------|-----------------|------|

| | | | | |
|-------|-------|-------|-------|-------|
| ----- | ----- | ----- | ----- | ----- |
|-------|-------|-------|-------|-------|

| | | | | |
|---------------|----|----------|----------------|----------|
| PI WO 9842188 | A1 | 19981001 | WO 1998-US5792 | 19980324 |
|---------------|----|----------|----------------|----------|

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG,

KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
 NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
 UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,
 FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
 GA, GN, ML, MR, NE, SN, TD, TG
 US 6350784 B1 20020226 US 1997-824041 19970326
 AU 9867718 A1 19981020 AU 1998-67718 19980324
 AU 727339 B2 20001207
 BR 9807892 A 20000222 BR 1998-7892 19980324
 EP 980203 A1 20000223 EP 1998-913086 19980324
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 EE 9900436 A 20000417 EE 1999-436 19980324
 NZ 500002 A 20010928 NZ 1998-500002 19980324
 JP 2001527541 T2 20011225 JP 1998-545926 19980324
 NO 9904639 A 19991124 NO 1999-4639 19990924
 MX 9908750 A 20000331 MX 1999-8750 19990924
 BG 63612 B1 20020731 BG 1999-103786 19991007
 PRAI US 1997-824041 A 19970326
 US 1996-600217 A2 19960212
 US 1996-646988 A2 19960508
 WO 1998-US5792 W 19980324

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2003 ACS
 AN 1990:610545 CAPLUS
 DN 113:210545
 TI Micronutrient status and human immunodeficiency virus (**HIV**)
 infection
 AU Bogden, John D.; Baker, Herman; Frank, Oscar; Perez, George; Kemp,
 Francis; Bruening, Kay; Louria, Donald
 CS New Jersey Med. Sch., Univ. Med. Dent., Newark, NJ, 07103-2757, USA
 SO Annals of the New York Academy of Sciences (1990), 587(Micronutr. Immune
 Funct./Cytokines Metab.), 189-95
 CODEN: ANYAA9; ISSN: 0077-8923
 DT Journal
 LA English

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2003 ACS
 AN 1990:232458 CAPLUS
 DN 112:232458
 TI Screening of anti-**HIV** activities in existing drugs which are
 suitable for long-term oral administration
 AU Asanaka, Miyuki; Kurimura, Takashi; Toya, Harumasa; Kato, Keiko
 CS Sch. Med., Tottori Univ., Yonago, 683, Japan
 SO Chemotherapy (Tokyo) (1990), 38(3), 249-55
 CODEN: NKRZAZ; ISSN: 0009-3165
 DT Journal
 LA English

=> d 19 8 all

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2003 ACS
 AN 1990:232458 CAPLUS
 DN 112:232458
 TI Screening of anti-**HIV** activities in existing drugs which are
 suitable for long-term oral administration
 AU Asanaka, Miyuki; Kurimura, Takashi; Toya, Harumasa; Kato, Keiko
 CS Sch. Med., Tottori Univ., Yonago, 683, Japan

SO Chemotherapy (Tokyo) (1990), 38(3), 249-55
 CODEN: NKRZAZ; ISSN: 0009-3165
 DT Journal
 LA English
 CC 10-5 (Microbial Biochemistry)
 AB Anti-**HIV** activities of 58 com. drugs available for long-term administration without significant side effects were investigated. Lorazepam, Ca hopanenate, prochorperazine maleate, amantadine HCl, perphenazine (I) and nitrazepam (II) were found to exhibit anti-**HIV** activity in MT-4 cells. But only I and II did so without cytotoxicity. In peripheral blood mononuclear cells, I exhibited only weak anti-**HIV** activity, while II showed none.
 ST AIDS **HIV** virus drug screening perphenazine
 IT Virucides and Virustats
 (for AIDS treatment, screening of)
 IT Immunodeficiency
 (acquired immune deficiency syndrome, perphenazine and other drugs for treatment of)
 IT Virus, animal
 (human immunodeficiency 1, perphenazine and other drugs effect on)
 IT 58-39-9, Perphenazine 84-02-6, Prochlorperazine maleate 146-22-5, Nitrazepam 665-66-7, Amantadine hydrochloride 846-49-1, Lorazepam 17097-76-6, Calcium hopanenate
 RL: BIOL (Biological study)
 (anti-**HIV** virus activity of, cytotoxicity in relation to)

=> FIL REGISTRY

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|--|------------------|---------------|
| FULL ESTIMATED COST | 93.70 | 125.07 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
| CA SUBSCRIBER PRICE | -5.21 | -5.21 |

FILE 'REGISTRY' ENTERED AT 15:37:52 ON 07 JUL 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 JUL 2003 HIGHEST RN 543672-54-4
 DICTIONARY FILE UPDATES: 6 JUL 2003 HIGHEST RN 543672-54-4

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> S 17097-76-6/RN

L12

1 17097-76-6/RN

=> SET NOTICE 1 DISPLAY

NOTICE SET TO 1 U.S. DOLLAR FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=> D L12 SQIDE 1-

YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y
THE ESTIMATED COST FOR THIS REQUEST IS 5.63 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L12 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS

RN 17097-76-6 REGISTRY

CN Butanoic acid, 4-[(2R)-2,4-dihydroxy-3,3-dimethyl-1-oxobutyl]amino]-, calcium salt (2:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Butanoic acid, 4-[(2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)amino]-, calcium salt (2:1), (R)-

CN Butyric acid, 4-(2,4-dihydroxy-3,3-dimethylbutyramido)-, calcium salt (2:1), D-(+)- (8CI)

OTHER NAMES:

CN Calcium D-(+)-homopantothenate

CN Calcium D-homopantothenate

CN Calcium homopantothenate

CN Calcium hopanenate

CN D-(+)-Homopantothenic acid calcium salt

CN Hopanenate calcium

CN Pantogam

CN Vivant

FS STEREOSEARCH


MF C10 H19 N 05 . 1/2 Ca

CI COM

LC STN Files: ADISNEWS, AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, DDFU, DRUGU, EMBASE, IPA, PHAR, PHARMASEARCH, PROMT, RTECS*, TOXCENTER, USAN
(*File contains numerically searchable property data)

CRN (18679-90-8)

Absolute stereochemistry.



●1/2 Ca

115 REFERENCES IN FILE CA (1957 TO DATE)

115 REFERENCES IN FILE CAPLUS (1957 TO DATE)

=> SET NOTICE LOGIN DISPLAY

NOTICE SET TO OFF FOR DISPLAY COMMAND
SET COMMAND COMPLETED

⇒

=> file caplus
 COST IN U.S. DOLLARS SINCE FILE TOTAL
 ENTRY SESSION
 FULL ESTIMATED COST 3.68 128.75
 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
 ENTRY SESSION
 CA SUBSCRIBER PRICE 0.00 -5.21

FILE 'CAPLUS' ENTERED AT 15:40:49 ON 07 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Jul 2003 VOL 139 ISS 2
FILE LAST UPDATED: 6 Jul 2003 (20030706/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 15:19:02 ON 07 JUL 2003)

FILE 'REGISTRY' ENTERED AT 15:19:14 ON 07 JUL 2003

L1 101 S PANTHENIC ACID
L2 2 S VITAMIN B5
L3 2 S VITAMIN B3
L4 1 S L2 NOT L3

FILE 'CAPLUS' ENTERED AT 15:20:40 ON 07 JUL 2003

| | | | |
|-----|-------|---|--------------|
| L5 | 5882 | S | L1 |
| | | | E RETROVIRAL |
| L6 | 13948 | S | E1-E6 |
| L7 | 50063 | S | HIV |
| L8 | 61642 | S | L7 OR L6 |
| L9 | 8 | S | L5 AND L8 |
| L10 | 21260 | S | VITAMIN D |
| L11 | 33 | S | L10 AND L8 |

FILE 'REGISTRY' ENTERED AT 15:37:52 ON 07 JUL 2003

FILE REGISTERED ENTERED AT 13:37:52
L12 1 S 17097-76-6/RN
SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

FILE 'CAPLUS' ENTERED AT 15:40:49 ON 07 JUL 2003

=> s 12
L13 5412 L2

=> s 13
L14 11658 L3

=> s 113 and 18
L15 4 L13 AND L8

=> d 115 1-4

L15 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS
AN 2002:745859 CAPLUS
DN 137:277454
TI A pantothenate auxotroph of *Mycobacterium tuberculosis* is highly attenuated and protects mice against tuberculosis
AU Sambandamurthy, Vasan K.; Wang, Xiaojuan; Chen, Bing; Russell, Robert G.; Derrick, Steven; Collins, Frank M.; Morris, Sheldon L.; Jacobs, William R.
CS Howard Hughes Medical Institute, Albert Einstein College of Medicine, Bronx, NY, USA
SO *Nature Medicine* (New York, NY, United States) (2002), 8(10), 1171-1174
CODEN: NAMEFI; ISSN: 1078-8956
PB Nature Publishing Group
DT Journal
LA English
RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS
AN 2001:6065 CAPLUS
DN 134:37051
TI Method for immune-system strengthening and development of a lipid transporter for anti-**HIV** and antibacterial gene therapy
IN Worm, Richard; Correa, Michel; Mavoungou, Donatien
PA Can.
SO Fr. Demande, 16 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-------------------|------|----------|-----------------|----------|
| PI FR 2792201 | A1 | 20001020 | FR 1999-4706 | 19990415 |
| PI FR 2792201 | B1 | 20011102 | | |
| PRAI FR 1999-4706 | | 19990415 | | |

L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS
AN 1998:661494 CAPLUS
DN 129:298375
TI Antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases
IN Squires, Meryl
PA USA
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|------|-----------------|------|
| | | | | |

PI WO 9842188 A1 19981001 WO 1998-US5792 19980324
 W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
 DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG,
 KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
 NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
 UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,
 FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
 GA, GN, ML, MR, NE, SN, TD, TG
 US 6350784 B1 20020226 US 1997-824041 19970326
 AU 9867718 A1 19981020 AU 1998-67718 19980324
 AU 727339 B2 20001207
 BR 9807892 A 20000222 BR 1998-7892 19980324
 EP 980203 A1 20000223 EP 1998-913086 19980324
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 EE 9900436 A 20000417 EE 1999-436 19980324
 NZ 500002 A 20010928 NZ 1998-500002 19980324
 JP 2001527541 T2 20011225 JP 1998-545926 19980324
 NO 9904639 A 19991124 NO 1999-4639 19990924
 MX 9908750 A 20000331 MX 1999-8750 19990924
 BG 63612 B1 20020731 BG 1999-103786 19991007
 PRAI US 1997-824041 A 19970326
 US 1996-600217 A2 19960212
 US 1996-646988 A2 19960508
 WO 1998-US5792 W 19980324

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS
 AN 1990:610545 CAPLUS
 DN 113:210545
 TI Micronutrient status and human immunodeficiency virus (**HIV**)
 infection
 AU Bogden, John D.; Baker, Herman; Frank, Oscar; Perez, George; Kemp,
 Francis; Bruening, Kay; Louria, Donald
 CS New Jersey Med. Sch., Univ. Med. Dent., Newark, NJ, 07103-2757, USA
 SO Annals of the New York Academy of Sciences (1990), 587(Micronutr. Immune
 Funct./Cytokines Metab.), 189-95
 CODEN: ANYAA9; ISSN: 0077-8923
 DT Journal
 LA English

=> d 115 3 4 all

L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS
 AN 1998:661494 CAPLUS
 DN 129:298375
 TI Antimicrobial prevention and treatment of human immunodeficiency virus and
 other infectious diseases
 IN Squires, Meryl
 PA USA
 SO PCT Int. Appl., 99 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A01N033-12
 ICS A61K031-14
 CC 1-5 (Pharmacology)
 Section cross-reference(s): 63
 FAN.CNT 5

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9842188 | A1 | 19981001 | WO 1998-US5792 | 19980324 |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | US 6350784 | B1 | 20020226 | US 1997-824041 | 19970326 |
| | AU 9867718 | A1 | 19981020 | AU 1998-67718 | 19980324 |
| | AU 727339 | B2 | 20001207 | | |
| | BR 9807892 | A | 20000222 | BR 1998-7892 | 19980324 |
| | EP 980203 | A1 | 20000223 | EP 1998-913086 | 19980324 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | EE 9900436 | A | 20000417 | EE 1999-436 | 19980324 |
| | NZ 500002 | A | 20010928 | NZ 1998-500002 | 19980324 |
| | JP 2001527541 | T2 | 20011225 | JP 1998-545926 | 19980324 |
| | NO 9904639 | A | 19991124 | NO 1999-4639 | 19990924 |
| | MX 9908750 | A | 20000331 | MX 1999-8750 | 19990924 |
| | BG 63612 | B1 | 20020731 | BG 1999-103786 | 19991007 |
| PRAI | US 1997-824041 | A | 19970326 | | |
| | US 1996-600217 | A2 | 19960212 | | |
| | US 1996-646988 | A2 | 19960508 | | |
| | WO 1998-US5792 | W | 19980324 | | |
| AB | An improved medical treatment and medicine is provided to quickly and safely resolve HIV and other microbial infections. The inexpensive medicine can be self administered and maintained for the prescribed time. The attractive medicine comprises an antimicrobial conc. comprising microbe inhibitors, phytochems. or isolates. Desirably, the effective medicine comprises a surfactant and an aq. carrier or solvent and a nutrient. In the preferred form, the medicine comprises: Echinacea and Commiphora myrrha phytochems., benzalkonium chloride, a sterile water soln., and folic acid. | | | | |
| ST | phytochem nutrient antimicrobial HIV ; Echinacea Commiphora phytochem surfactant antimicrobial HIV ; folic acid phytochem antimicrobial HIV | | | | |
| IT | Labia
Lip
Lymph node
Lymphatic system
T cell (lymphocyte)
(administration to; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases) | | | | |
| IT | Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkylbenzyldimethyl, bromides; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases) | | | | |
| IT | Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkylbenzyldimethyl, chlorides; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases) | | | | |
| IT | Surfactants
(amphoteric; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases) | | | | |
| IT | Bacilli
(anaerobic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases) | | | | |
| IT | Allium | | | | |

Anise
Arctostaphylos
Artemisia
Baptisia
Calendula
Capsicum
Carum
Compositae (Asteraceae)
Coriandrum
Echinacea angustifolia
Echinacea atribactilus
Echinacea pallida
Echinacea purpurea
Echinacea vegetalis
Eucalyptus
Eugenia mytacea
Gentian (Gentiana)
Inula
Juniper (Juniperus)
Labiatae (Lamiaceae)
Meliosma
Mentha
Mentha aquatica hypeuria
Myroxylon
Origanum
Parthenium integrifolium
Plantago
Rosemary
Ruta
Sage (Salvia)
(antimicrobial isolates of; antimicrobial prevention and treatment of
human immunodeficiency virus and other infectious diseases)

IT Adenoviridae
Antibacterial agents
Antimicrobial agents
Antiviral agents
Arbovirus
Arenavirus
Bird (Aves)
Cat (Felis catus)
Cattle
Commiphora erythraea
Commiphora molmol
Commiphora myrrha
Coronavirus
Cytomegalovirus
Dog (Canis familiaris)
Drug delivery systems
Gums and Mucilages
Horse (Equus caballus)
Human herpesvirus 1
Human herpesvirus 2
Human herpesvirus 3
Human herpesvirus 4
Human immunodeficiency virus
Human parainfluenza virus
Influenza virus
Livestock
Mycobacterium
Nutrients
Papillomavirus
Picornaviridae

Rodent
Sexually transmitted diseases
Sheep
Staphylococcus
Streptococcus
Surfactants
Swine
 (antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Amides, biological studies
Anthocyanins
Enzymes, biological studies
Natural products, pharmaceutical
Polyacetylenes, biological studies
Polysaccharides, biological studies
Proteins, general, biological studies
Sesquiterpenes
Tannins
Vitamins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Encephalitis
Meningitis
 (bacterial and viral; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Detergents
Surfactants
 (cationic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Inflammation
 (cellulitis; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Polyacetylenes, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (derivs.; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Vitamins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (fat-sol.; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
 (injections; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Mouth
 (mucosa, administration to; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
 (nasal; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Surfactants
 (nonionic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
 (ophthalmic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Animal tissue
(periacinal, administration to; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Plant (Embryophyta)
(phytochems.; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Intestine
(rectum, anus, administration to; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(sublingual; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(surfactant; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Carboxylic acids, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetraenoic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(topical, and systemic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(vaginal; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Vitamins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(water-sol.; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Surfactants
(zwitterionic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT 50-81-7, Ascorbic acid, biological studies 57-10-3, Hexadecanoic acid, biological studies 57-88-5, Cholesterol, biological studies 58-86-6, Xylose, biological studies 59-23-4, Galactose, biological studies 59-30-3, Folic acid, biological studies 59-43-8, Thiamin, biological studies 59-67-6, Niacin, biological studies 64-19-7, Acetic acid, biological studies 68-19-9, Vitamin B12 76-49-3, Bornyl acetate 79-83-4, Vitamin B5 80-56-8, .alpha.-Pinene 83-46-5, .beta.-Sitosterol 83-48-7, Stigmasterol 83-88-5, Riboflavin, biological studies 87-44-5, Caryophyllene 87-69-4, biological studies 97-53-0, Eugenol 104-55-2, Cinnamaldehyde 108-39-4, biological studies 112-85-6D, Docosanoic acid, derivs. 117-39-5, Quercetin 121-33-5, Vanillin 122-03-2, Cuminaldehyde 127-91-3, .beta.-Pinene 138-86-3, Limonene 147-81-9, Arabinose 153-18-4, Rutin 327-97-9, Chlorogenic acid 331-39-5, Caffeic acid 331-39-5D, Caffeic acid, esters 474-58-8 474-62-4, Campesterol 480-10-4, Kaempferol-3-glucoside 482-35-9, Quercetin-3-glucoside 482-36-0 491-70-3, Luteolin 495-62-5, .gamma.-Bisabolene 504-97-2, Echinacein 507-70-0, Borneol 520-18-3, Kaempferol 520-36-5, Apigenin 534-61-2, Isochlorogenic acid 536-60-7, Cumaric alcohol 548-75-4, Quercetagetin-7-glucoside 563-83-7 593-50-0, n-Triacanol 604-80-8 638-96-0, .alpha.-Amyrone 639-99-6, Elemol 643-20-9D, Pyrrolizidine, alkaloid 1139-30-6, Caryophyllene epoxide 1406-16-2, Vitamin D 1406-18-4, Vitamin E 2450-53-5, 3,5-Dicaffeoylquinic acid 3562-36-5, Pontica epoxide 3615-41-6, Rhamnose 3812-32-6, Carbonate, biological studies

3943-97-3, Methyl p-hydroxycinnamate 4120-73-4, 4-O-Methylglucuronic acid 5373-11-5, Luteolin-7-glucoside 5937-48-4, 3-epi-.alpha.-Amyrin 6537-80-0, Chicoric acid 6556-12-3, Glucuronic acid 7235-40-7, .beta.-Carotene 7439-89-6, Iron, biological studies 7439-95-4, Magnesium, biological studies 7439-96-5, Manganese, biological studies 7440-09-7, Potassium, biological studies 7440-23-5, Sodium, biological studies 7440-48-4, Cobalt, biological studies 7440-70-2, Calcium, biological studies 7723-14-0, Phosphorus, biological studies 7782-49-2, Selenium, biological studies 8001-18-1, Echinacin 8059-24-3, Vitamin B6 9005-80-5, Inulin 9014-63-5D, Xylan, derivs. 9036-66-2, Arabinogalactan 9040-28-2, 4-O-Methylglucuronoxylaranose 11006-56-7, Vitamin B15 11103-57-4, Vitamin A 12001-79-5, Vitamin K 12627-13-3, Silicate 13360-61-7, 1-Pentadecene 14808-79-8, Sulfate, biological studies 16887-00-6, Chloride, biological studies 17627-44-0, .alpha.-Bisabolene 17650-84-9 18668-90-1, 8-Pentadecen-2-one 18794-84-8, .beta.-Farnesene 19912-61-9, Furanodiene 20493-56-5, Curzerenone 23986-74-5, Germacrene D 24268-41-5, Furanodienone 24738-51-0 25067-58-7, Polyacetylene 25067-58-7D, Polyacetylene, derivs. 27214-55-7, Quercetin-3-xyloside 28028-64-0, Germacrene 29350-73-0, Cadinene 30964-13-7, Cynarin 36129-21-2 39007-92-6, Commiferin 47705-70-4 52525-35-6 57378-72-0 59440-97-0, Echinolone 61276-17-3, Verbascoside 67879-58-7 69350-61-4, Epishybunol 74282-22-7 75081-19-5, Pentadecadiene 76963-26-3 80151-77-5, Tussilagine 82854-37-3, Echinacoside 84744-28-5 91108-32-6, Isotussilagine 94977-38-5 99119-75-2 99119-76-3 116752-09-1 116752-10-4 117841-81-3 118853-85-3 125199-93-1 148879-89-4, Commiphorinic acid 149531-55-5, .alpha.-Commiphoric acid 149531-56-6, .beta.-Commiphoric acid 149531-57-7, .gamma.-Commiphoric acid 162666-19-5, Inuloidin 205510-62-9, Echinacin B 214041-69-7 214041-70-0 214041-71-1 214041-72-2 214041-73-3 214405-10-4, Heerabolene 214405-11-5, .alpha.-Heerabomyrrhol 214405-12-6, .beta.-Heerabomyrrhol 214405-13-7, Heeraboresene 214405-44-4, Viracea 1 214405-45-5, Viracea 2 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT 120-32-1, o-Benzyl-p-chlorophenol 139-07-1, Lauryldimethylbenzylammonium chloride 5538-94-3, Dioctyldimethylammonium chloride 7173-51-5, Didecyldimethylammonium chloride 32426-11-2, Octyldecyldimethylammonium chloride

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT 12001-76-2, Vitamin B

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(complex; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT 79-14-1D, Glycolic acid, derivs.

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(surfactant; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Bryant; US 4797420 A 1989 CAPLUS

(2) Hempel; DE 3521143 A1 CAPLUS Acc No 1987:483909 1986 CAPLUS

(3) Silverman; US 5455033 A 1995

(4) Tyle, R; "The Honest Herbal, A Sensible Guide to the Use of Herbs and Related Remedies", 3rd Edition 1993, P115

(5) Tyler, V; Herbs of choice, The Therapeutic Use of Phytomedicinals 1994,
P181
(6) Wainberg; Arch AIDS Res, CAPLUS Acc No 1988:147004 1987, V1(1), P57 CAPLUS

L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS
AN 1990:610545 CAPLUS
DN 113:210545
TI Micronutrient status and human immunodeficiency virus (**HIV**)
infection
AU Bogden, John D.; Baker, Herman; Frank, Oscar; Perez, George; Kemp,
Francis; Bruening, Kay; Louria, Donald
CS New Jersey Med. Sch., Univ. Med. Dent., Newark, NJ, 07103-2757, USA
SO Annals of the New York Academy of Sciences (1990), 587(Micronutr. Immune
Funct./Cytokines Metab.), 189-95
CODEN: ANYAA9; ISSN: 0077-8923
DT Journal
LA English
CC 18-1 (Animal Nutrition)
Section cross-reference(s): 14, 15
AB Humans with **HIV** infections generally showed .gtoreq.1 abnormally
low level of plasma micronutrients (e.g. minerals, vitamins). Abnormally
high levels of some micronutrients were also found, but these were
attributed to the ingestion of high supplement amts.
ST micronutrient nutrition human immunodeficiency virus infection;
HIV infection diet micronutrient
IT Carotenes and Carotenoids, biological studies
Trace elements, biological studies
Vitamins
RL: BIOL (Biological study)
(**HIV** virus infection in humans in relation to nutritional
status of)
IT Virus, animal
(human immunodeficiency 1, humans infection by, micronutrient status in
relation to)
IT Nutrients
(micro-, **HIV** virus infection in humans in relation to
nutritional status of)
IT 50-81-7, Vitamin C, biological studies 58-85-5, Biotin 59-30-3, Folic
acid, biological studies 59-43-8, Thiamin, biological studies 59-67-6,
Niacin, biological studies 62-49-7, Choline 68-19-9, Vitamin B12
79-83-4, Pantothenic acid 83-88-5, Riboflavin, biological
studies 87-89-8, Inositol 541-15-1, Carnitine 1406-18-4, Vitamin E
7439-95-4, Magnesium, biological studies 7440-50-8, Copper, biological
studies 7440-66-6, Zinc, biological studies 7440-70-2, Calcium,
biological studies 8059-24-3, Vitamin B6 11103-57-4, Vitamin A
22150-76-1, Bioperin
RL: BIOL (Biological study)
(**HIV** virus infection in humans in relation to nutritional
status of)

=> s 114 an d18

MISSING OPERATOR L14 AN

The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> d 114 and 18

L8 IS NOT VALID HERE

For an explanation, enter "HELP DISPLAY".

=> s 114 and 18

L16 19 L14 AND L8

=> s 116 not 115
L17 15 L16 NOT L15

=> d 117 1-15

L17 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2003 ACS
AN 2003:205993 CAPLUS
DN 138:268107
TI Nicotinamide: An oral antimicrobial agent with activity against both
Mycobacterium tuberculosis and human immunodeficiency virus
AU Murray, Michael F.
CS Department of Medicine, Brigham and Women's Hospital, Harvard University,
Boston, MA, USA
SO Clinical Infectious Diseases (2003), 36(4), 453-460
CODEN: CIDIEL; ISSN: 1058-4838
PB University of Chicago Press
DT Journal; General Review
LA English
RE.CNT 72 THERE ARE 72 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2003 ACS
AN 2003:154399 CAPLUS
DN 138:204936
TI Preparation of heterocyclic compds. as integrase inhibiting antiviral
agents
IN Kiyama, Ryuichi; Kanda, Yasuhiko; Tada, Yukio; Fujishita, Toshio;
Kawasaji, Takashi; Takechi, Shozo; Fuji, Masahiro
PA Shionogi & Co., Ltd., Japan
SO PCT Int. Appl., 663 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-------|---|------------|----------|-----------------|----------|
| ----- | ----- | ----- | ----- | ----- | ----- |
| PI | WO 2003016275 | A1 | 20030227 | WO 2002-JP8108 | 20020808 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG | | | | |
| PRAI | JP 2001-245071 | A | 20010810 | | |
| | JP 2001-370860 | A | 20011205 | | |
| | JP 2002-191483 | A | 20020628 | | |
| OS | MARPAT | 138:204936 | | | |

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS
AN 2002:657938 CAPLUS
DN 137:190753
TI Transdermal therapeutic system containing testosterone and method for the
production
IN Theobald, Frank

PA LTS Lohmann Therapie-Systeme A.-G., Germany

SO PCT Int. Appl., 16 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|------------------|--|----------|------------------|----------|
| PI | WO 2002066018 | A2 | 20020829 | WO 2002-EP1258 | 20020207 |
| | WO 2002066018 | A3 | 20030424 | | |
| | W: | AU, BR, CA, CN, JP, KR, MX, US, ZA | | | |
| | RW: | AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR | | | |
| | DE 10107663 | A1 | 20020905 | DE 2001-10107663 | 20010219 |
| PRAI | DE 2001-10107663 | A | 20010219 | | |

L17 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2003 ACS

AN 2002:51504 CAPLUS

DN 136:112623

TI Zinc finger motif sequences from herpes simplex virus protein IE63 and uses thereof in drug screening for treating herpesvirus infection

IN Clements, John Barklie; MacLean, Alasdair Roderick

PA The University Court of the University of Glasgow, UK

SO PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|--|----------|-----------------|----------|
| PI | WO 2002004492 | A2 | 20020117 | WO 2001-GB3114 | 20010711 |
| | WO 2002004492 | A3 | 20020510 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| | EP 1299725 | A2 | 20030409 | EP 2001-949666 | 20010711 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | |
| PRAI | GB 2000-16890 | A | 20000711 | | |
| | WO 2001-GB3114 | W | 20010711 | | |

L17 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2003 ACS

AN 2001:504998 CAPLUS

DN 136:273127

TI Increased plasma tryptophan in HIV-infected patients treated with pharmacologic doses of nicotinamide

AU Murray, M. F.; Langan, M.; MacGregor, R. R.

CS Department of Medicine, Brigham and Women's Hospital, Harvard University, Boston, MA, USA

SO Nutrition (New York, NY, United States) (2001), 17(7/8), 654-656

CODEN: NUTRER; ISSN: 0899-9007

PB Elsevier Science Inc.

DT Journal

LA English

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2003 ACS
 AN 1999:454270 CAPLUS
 DN 131:82943
 TI Compositions and methods for identifying therapeutic agents and for
 treating cells having double minute DNA
 IN Wahl, Geoffrey M.; Shepard, H. Michael; Shimizu, Noriaki
 PA Newbiotics, Inc., USA; The Salk Institute; Kanda, Teru
 SO PCT Int. Appl., 80 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----------|--|-----------|----------|-----------------|----------|
| PI | WO 9935292 | A1 | 19990715 | WO 1999-US601 | 19990111 |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2318380 | AA | 19990715 | CA 1999-2318380 | 19990111 |
| | AU 9922217 | A1 | 19990726 | AU 1999-22217 | 19990111 |
| | EP 1070140 | A1 | 20010124 | EP 1999-902175 | 19990111 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI | | | | |
| | BR 9906926 | A | 20020115 | BR 1999-6926 | 19990111 |
| | JP 2002510033 | T2 | 20020402 | JP 2000-527673 | 19990111 |
| PRAI | US 1998-71146P | P | 19980112 | | |
| | US 1998-77644P | P | 19980311 | | |
| | WO 1999-US601 | W | 19990111 | | |
| OS | MARPAT | 131:82943 | | | |
| RE.CNT 5 | THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT | | | | |

CS Department of Medical and Surgical Sciences, University of Torino, Turin,
 Italy
 SO Journal of Biological Regulators and Homeostatic Agents (1996), 10(1),
 13-18
 CODEN: JBRAER; ISSN: 0393-974X
 PB Wichtig
 DT Journal
 LA English

L17 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2003 ACS
 AN 1996:256739 CAPLUS
 DN 124:299031
 TI Growth control for cells encapsulated within bioartificial organs
 IN Schinstine, Malcolm; Shoichet, Molly S.; Gentile, Frank T.; Hammang,
 Joseph P.; Holland, Laura M.; Cain, Brian M.; Doherty, Edward J.; Winn,
 Shelley R.; Aebischer, Patrick
 PA Cytotherapeutics, Inc., USA
 SO PCT Int. Appl., 83 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|---|----------|-----------------|----------|
| PI | WO 9602646 | A2 | 19960201 | WO 1995-US9281 | 19950720 |
| | WO 9602646 | A3 | 19960517 | | |
| | W: | AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI,
GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD,
MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ,
TM, TT | | | |
| | RW: | KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT,
LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE,
SN, TD, TG | | | |
| | US 5935849 | A | 19990810 | US 1994-279773 | 19940720 |
| | US 5843431 | A | 19981201 | US 1995-432698 | 19950509 |
| | AU 9531422 | A1 | 19960216 | AU 1995-31422 | 19950720 |
| | AU 698624 | B2 | 19981105 | | |
| | EP 771350 | A1 | 19970507 | EP 1995-927373 | 19950720 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | |
| | JP 10506266 | T2 | 19980623 | JP 1995-505271 | 19950720 |
| | BR 9508312 | A | 19990601 | BR 1995-8312 | 19950720 |
| | NO 9700156 | A | 19970320 | NO 1997-156 | 19970114 |
| | FI 9700217 | A | 19970117 | FI 1997-217 | 19970117 |
| PRAI | US 1994-279773 | A | 19940720 | | |
| | US 1995-432698 | A | 19950509 | | |
| | WO 1995-US9281 | W | 19950720 | | |

L17 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2003 ACS
 AN 1995:958459 CAPLUS
 DN 124:7065
 TI Biochemically active agents for chemical catalysis and cell receptor
 activation
 IN Kossovsky, Nir; Sponsler, Edward; Gelman, Andrew; Rajguru, Samir
 PA The Regents of the University of California, USA
 SO U.S., 13 pp. Cont.-in-part of U.S. 5,334,394.
 CODEN: USXXAM

DT Patent
 LA English
 FAN.CNT 10

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|------------|------|----------|-----------------|----------|
| PI | US 5460830 | A | 19951024 | US 1993-145870 | 19931101 |

| | | | | |
|---|----|----------|-----------------|----------|
| US 5219577 | A | 19930615 | US 1990-542255 | 19900622 |
| US 5178882 | A | 19930112 | US 1991-690601 | 19910424 |
| JP 05255111 | A2 | 19931005 | JP 1991-178805 | 19910624 |
| JP 2932406 | B2 | 19990809 | | |
| US 5334394 | A | 19940802 | US 1993-199 | 19930104 |
| US 5462750 | A | 19951031 | US 1994-225100 | 19940408 |
| WO 9512392 | A1 | 19950511 | WO 1994-US12515 | 19941031 |
| W: CA, JP | | | | |
| RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| CA 2174244 | AA | 19950511 | CA 1994-2174244 | 19941031 |
| EP 726767 | A1 | 19960821 | EP 1995-901094 | 19941031 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| JP 09504790 | T2 | 19970513 | JP 1994-513349 | 19941031 |
| PRAI US 1990-542255 19900622 | | | | |
| US 1991-690601 19910424 | | | | |
| US 1993-199 19930104 | | | | |
| US 1993-986 19930106 | | | | |
| US 1993-145870 19931101 | | | | |
| US 1993-146536 19931101 | | | | |
| US 1993-147751 19931104 | | | | |
| WO 1994-US12515 19941031 | | | | |

L17 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2003 ACS
 AN 1995:673568 CAPLUS
 DN 123:109959
 TI **HIV** infection decreases intracellular nicotinamide adenine dinucleotide [NAD]
 AU Murray, Michael F.; Nghiem, Michael; Srinivasan, Alagarsamy
 CS Dep. Med., Univ. PA Sch. Med., Philadelphia, PA, USA
 SO Biochemical and Biophysical Research Communications (1995), 212(1), 126-31
 CODEN: BBRCA9; ISSN: 0006-291X
 PB Academic
 DT Journal
 LA English

L17 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2003 ACS
 AN 1995:590755 CAPLUS
 DN 123:357
 TI Nicotinamide inhibits **HIV-1** in both acute and chronic in vitro infection
 AU Murray, Michael F.; Srinivasan, Alagarsamy
 CS Department of Medicine, University of PA School of Medicine, Philadelphia, Panama
 SO Biochemical and Biophysical Research Communications (1995), 210(3), 954-9
 CODEN: BBRCA9; ISSN: 0006-291X
 PB Academic
 DT Journal
 LA English

L17 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS
 AN 1995:556533 CAPLUS
 DN 123:143841
 TI Synthesis and antiviral evaluation of fluorinated dipyridodiazepinones and dipyridodiazepines (nevirapine derivatives)
 AU Boyode, B. P.; Sinet, M.; Barese, A.; Forestier-Roux, M.-A.; Condom, R.; Ayi, I. A.; Kirn, A.; Moog, C.; Guedj, R.
 CS Faculte Sciences, Universite Nice-Sophia Antipolis, Nice, F-06108, Fr.
 SO Antiviral Chemistry & Chemotherapy (1995), 6(3), 162-8
 CODEN: ACCHEH; ISSN: 0956-3202
 PB Blackwell
 DT Journal
 LA English

L17 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2003 ACS
 AN 1991:622844 CAPLUS
 DN 115:222844
 TI Inhibitors of ADP-ribosylation as antiviral drugs: experimental study on the model of **HIV** infection
 AU Krasil'nikov, I. I.; Kalnina, L. B.; Korneeva, M. N.; Nosik, D. N.; Zlobin, A. Yu.; Vladimirov, V. G.; L'vov, D. K.
 CS Inst. Virusol. im. Ivanovskogo, Moscow, USSR
 SO Voprosy Virusologii (1991), 36(3), 216-18
 CODEN: VVIRAT; ISSN: 0507-4088
 DT Journal
 LA Russian

L17 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2003 ACS
 AN 1990:151841 CAPLUS
 DN 112:151841
 TI Preparation of glycerophosphate derivatives as animal virucides
 IN Shenfeld, Avner
 PA Scienscope International N. V., Neth.
 SO Eur. Pat. Appl., 22 pp.
 CODEN: EPXXDW

DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | EP 316117 | A1 | 19890517 | EP 1988-310391 | 19881104 |
| | R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE | | | | |
| | WO 8904314 | A1 | 19890518 | WO 1988-NL48 | 19881102 |
| | W: AU, BB, BG, BR, DK, FI, HU, JP, KP, KR, LK, MC, MG, MW, NL, NO, RO, SD, SU | | | | |
| | RW: BJ, CF, CG, CM, GA, ML, MR, SN, TD, TG | | | | |
| | AU 8826199 | A1 | 19890601 | AU 1988-26199 | 19881102 |
| | JP 02502096 | T2 | 19900712 | JP 1988-508750 | 19881102 |
| | FI 8903279 | A | 19890705 | FI 1989-3279 | 19890705 |
| PRAI | IL 1987-84387 | | 19871106 | | |
| | WO 1988-NL48 | | 19881102 | | |
| OS | MARPAT 112:151841 | | | | |

=> d 117 15 all

L17 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2003 ACS
 AN 1990:151841 CAPLUS
 DN 112:151841
 TI Preparation of glycerophosphate derivatives as animal virucides
 IN Shenfeld, Avner
 PA Scienscope International N. V., Neth.
 SO Eur. Pat. Appl., 22 pp.
 CODEN: EPXXDW

DT Patent
 LA English

IC ICM C07F009-10
 ICS C07F009-09; C07F009-58; A61K031-66
 CC 1-5 (Pharmacology)
 Section cross-reference(s): 27

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | EP 316117 | A1 | 19890517 | EP 1988-310391 | 19881104 |
| | R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE | | | | |

| | | | | |
|--|----|----------|----------------|----------|
| WO 8904314 | A1 | 19890518 | WO 1988-NL48 | 19881102 |
| W: AU, BB, BG, BR, DK, FI, HU, JP, KP, KR, LK, MC, MG, MW, NL, NO, | | | | |
| RO, SD, SU | | | | |
| RW: BJ, CF, CG, CM, GA, ML, MR, SN, TD, TG | | | | |
| AU 8826199 | A1 | 19890601 | AU 1988-26199 | 19881102 |
| JP 02502096 | T2 | 19900712 | JP 1988-508750 | 19881102 |
| FI 8903279 | A | 19890705 | FI 1989-3279 | 19890705 |
| PRAI IL 1987-84387 | | 19871106 | | |
| WO 1988-NL48 | | 19881102 | | |
| OS MARPAT 112:151841 | | | | |
| AB The acylglycerophosphate esters R1OCH2CH(OR2)CH2OP(O)(O-)GAzR3 [R1, R2 = H, fatty acyl; A = CH2, polymethylene, oxapolymethylene, thiapolymethylene, etc. R3 = (un)substituted Ph or pyridinium, etc.; G = O, S; Z = 0, 1-18] are prep'd. as virucides, suitable for treating human immunodeficiency virus (HIV) infections. 2-Hydroxyethyl-1-nicotinamide chloride (prepn. given) was transphosphatidylated enzymically, by the method of Eibel and Kovatchev (1981), to give phosphatidyl-2-hydroxyethyl-1-nicotinamide (I). I (20 .mu.g/mL) totally controlled HIV , in vitro, as shown by the method of Moore, et al. (1978). | | | | |
| ST virucide animal phospholipid; glycerophosphate deriv prepn AIDS drug | | | | |
| IT Phosphatidylethanolamines | | | | |
| RL: RCT (Reactant); RACT (Reactant or reagent) | | | | |
| (acetylation of) | | | | |
| IT Phospholipids, biological studies | | | | |
| RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study) | | | | |
| (virucides, animal) | | | | |
| IT Immunodeficiency | | | | |
| (acquired immune deficiency syndrome, treatment of, with reaction products of acylglycerophosphates with alcs. and thiols) | | | | |
| IT Phosphatidic acids | | | | |
| RL: SPN (Synthetic preparation); PREP (Preparation) | | | | |
| (esters, prepn. of, as animal virucides) | | | | |
| IT Virucides and Virustats | | | | |
| (medical, reaction products of acid glycerophosphates with alcs. or thiols) | | | | |
| IT Phosphatidylethanolamines | | | | |
| RL: SPN (Synthetic preparation); PREP (Preparation) | | | | |
| (reaction products, with acetic anhydride, prepn. of, as animal virucide) | | | | |
| IT 98-92-0, Nicotinamide | | | | |
| RL: BIOL (Biological study) | | | | |
| (condensation of, with chloroethanol) | | | | |
| IT 107-07-3, 2-Chloroethanol, biological studies | | | | |
| RL: BIOL (Biological study) | | | | |
| (condensation of, with nicotinamide). | | | | |
| IT 126235-31-2P | | | | |
| RL: SPN (Synthetic preparation); PREP (Preparation) | | | | |
| (prepn. and transphosphatidylation of) | | | | |
| IT 58-27-5DP, reaction products with phosphatidylethanolamines 100-51-6DP, Benzenemethanol, reaction products with phosphatidic acids 108-24-7DP, reaction products with phosphatidylethanolamines 141-79-7DP, reaction products with phosphatidylethanolamines 126235-31-2DP, reaction products with phosphatidic acids | | | | |
| RL: SPN (Synthetic preparation); PREP (Preparation) | | | | |
| (prepn. of, as animal viricide) | | | | |
| IT 58-27-5, Menadione | | | | |
| RL: RCT (Reactant); RACT (Reactant or reagent) | | | | |
| (reaction of, with phosphatidylethanolamine) | | | | |

=> d 117 14 all

L17 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2003 ACS
AN 1991:622844 CAPLUS
DN 115:222844
TI Inhibitors of ADP-ribosylation as antiviral drugs: experimental study on the model of **HIV** infection
AU Krasil'nikov, I. I.; Kalnina, L. B.; Korneeva, M. N.; Nosik, D. N.; Zlobin, A. Yu.; Vladimirov, V. G.; L'vov, D. K.
CS Inst. Virusol. im. Ivanovskogo, Moscow, USSR
SO Voprosy Virusologii (1991), 36(3), 216-18
CODEN: VVIRAT; ISSN: 0507-4088
DT Journal
LA Russian
CC 1-5 (Pharmacology)
AB The antiviral effects of arom. carbonic acid amides including trisubstituted benzamides and nicotinamide were tested in lymphoblastoid cells infected with **HIV** virus. Five out of 8 substances tested had an antiviral activity which might be due to their capacity to inhibit ADP-ribosylation. By blocking ADP-ribosylation, the substances depressed DNA capacity for reparation, inhibited differentiation and transformation of cells, and had indirect effects on the reprodn. of viruses. The universal nature of the processes of NAD+-dependent ADP-ribosylation suggests that the range of antiviral activity of inhibitors of mono- and poly-ADP-ribosylation may not be limited only to **HIV** infection.
ST immunodeficiency virus benzamide deriv virucide ribosylation
IT Virucides and Virustats
 (benzamide derivs. as, on immunodeficiency virus, ADP-ribosylation inhibition in)
IT Glycosidation
 (ADP-ribosidation, benzamide derivs. virucidal effects in relation to inhibition of)
IT Virus, animal
 (human immunodeficiency 1, benzamide derivs. inhibition of, ADP-ribosylation in)
IT 55-21-0, Benzamide **98-92-0**, 3-Pyridinecarboxamide 645-09-0, 3-Nitrobenzamide 3544-24-9, 3-Aminobenzamide 5813-86-5, 3-Methoxybenzamide 58202-87-2 137084-97-0 137084-98-1
RL: PRP (Properties)
 (virucidal effects of, on immunodeficiency virus, ADP-ribosylation inhibition in)

=> d 117 12 all

L17 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2003 ACS
AN 1995:590755 CAPLUS
DN 123:357
TI Nicotinamide inhibits **HIV-1** in both acute and chronic in vitro infection
AU Murray, Michael F.; Srinivasan, Alagarsamy
CS Department of Medicine, University of PA School of Medicine, Philadelphia, Panama
SO Biochemical and Biophysical Research Communications (1995), 210(3), 954-9
CODEN: BBRCA9; ISSN: 0006-291X
PB Academic
DT Journal
LA English
CC 1-5 (Pharmacology)
AB **HIV-1** infected patients can manifest a no. of poorly understood conditions including dermatitis, dementia, and diarrhea. These conditions are in some ways suggestive of pellagra, the syndrome assocd. with niacin

depletion. We demonstrate here that nicotinamide, the amide form of niacin, inhibits **HIV-1** infection in cell culture. Neither nicotinic acid which is the alternative form of niacin, nor thiamine (another B complex vitamin), shows a similar degree of inhibition in tissue culture. This inhibition occurs in both primary cells and in established cell lines. In vitro models of acute and chronic **HIV** infection are demonstrated here to be inhibited by nicotinamide in a dose dependent manner when added in millimolar concns.

ST nicotinamide HIV1 infection inhibition
IT Virucides and Virustats
 (nicotinamide inhibition of **HIV-1** in acute and chronic in vitro infection)
IT Virus, animal
 (human immunodeficiency 1, nicotinamide inhibition of **HIV-1** in acute and chronic in vitro infection)
IT 98-92-0, Nicotinamide
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (inhibition of **HIV-1** in acute and chronic in vitro infection by)
IT 59-43-8, Thiamine, biological studies 59-67-6, Nicotinic acid, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (nicotinamide inhibition of **HIV-1** in acute and chronic in vitro infection comparison with)

=> s herpes or hsv or hhsv or cmv
 21482 HERPES
 9575 HSV
 0 HHSV
 5388 CMV
L18 27587 HERPES OR HSV OR HHSV OR CMV

=> s l18 and 18
L19 2073 L18 AND L8

=> d his

(FILE 'HOME' ENTERED AT 15:19:02 ON 07 JUL 2003)

FILE 'REGISTRY' ENTERED AT 15:19:14 ON 07 JUL 2003

L1 101 S PANTOTHENIC ACID
L2 2 S VITAMIN B5
L3 2 S VITAMIN B3
L4 1 S L2 NOT L3

FILE 'CAPLUS' ENTERED AT 15:20:40 ON 07 JUL 2003

L5 5882 S L1
 E RETROVIRAL
L6 13948 S E1-E6
L7 50063 S HIV
L8 61642 S L7 OR L6
L9 8 S L5 AND L8
L10 21260 S VITAMIN D
L11 33 S L10 AND L8

FILE 'REGISTRY' ENTERED AT 15:37:52 ON 07 JUL 2003

L12 1 S 17097-76-6/RN

SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

FILE 'CAPLUS' ENTERED AT 15:40:49 ON 07 JUL 2003

L13 5412 S L2
L14 11658 S L3
L15 4 S L13 AND L8
L16 19 S L14 AND L8
L17 15 S L16 NOT L15
L18 27587 S HERPES OR HSV OR HHSV OR CMV
L19 2073 S L18 AND L8

=> s 118 and 15
L20 6 L18 AND L5

=> d 120 1-6

L20 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS
AN 2003:93061 CAPLUS
DN 138:142477
TI Drug composition containing amino acids and Vitamin C for the prevention
of angina pectoris
IN Sibbe, Bernhard; Wiehrer, Walter
PA Germany
SO Ger. Offen., 6 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI DE 10128934 A1 20030206 DE 2001-10128934 20010618
PRAI DE 2001-10128934 20010618
RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS
AN 2002:928122 CAPLUS
DN 138:12504
TI Method for assaying biomolecules and other constituents using indicator
conjugates with synthetic nucleounits in lateral flow, liquid, and dry
chemistry techniques
IN Smith, Jack V.
PA USA
SO U.S. Pat. Appl. Publ., 46 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI US 2002182600 A1 20021205 US 2001-829563 20010411
PRAI US 2001-829563 20010411

L20 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS
AN 1998:293397 CAPLUS
DN 128:326546
TI Methods and compositions for dietary supplementation
IN Burgstiner, Carson B.
PA Burgstiner, Jacqueline Cook, USA
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--------|--|--|----------|-----------------|----------|
| PI | WO 9818491 | A1 | 19980507 | WO 1997-US19564 | 19971028 |
| | W: CA, JP, US | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| PRAI | US 1996-29403P | P | 19961028 | | |
| RE.CNT | 3 | THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD | | | |
| | | ALL CITATIONS AVAILABLE IN THE RE FORMAT | | | |

L20 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS
 AN 1996:370862 CAPLUS
 DN 125:57030
 TI Effects of B vitamin injection on bovine herpesvirus-1 infection and immunity in feed-restricted beef calves
 AU Dubeski, P. L.; d'Offay, J. M.; Owens, F. N.; Gill, D. R.
 CS Department Animal Science, Oklahoma State University, Stillwater, OK, 74078-0425, USA
 SO Journal of Animal Science (1996), 74(6), 1367-1374
 CODEN: JANSAG; ISSN: 0021-8812
 PB American Society of Animal Science
 DT Journal
 LA English

L20 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS
 AN 1986:45751 CAPLUS
 DN 104:45751
 TI Antiviral pharmaceutical preparations and their use
 IN Haines, Harold Gray; Dickens, Caroline Burgess
 PA Brigham, Dana, USA
 SO Eur. Pat. Appl., 44 pp.
 CODEN: EPXXDW
 DT Patent
 LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | EP 154344 | A2 | 19850911 | EP 1985-102607 | 19850307 |
| | EP 154344 | A3 | 19900613 | | |
| | EP 154344 | B1 | 19930707 | | |
| | R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE | | | | |
| | US 4628063 | A | 19861209 | US 1984-587398 | 19840308 |
| | WO 8503862 | A1 | 19850912 | WO 1985-US362 | 19850306 |
| | W: AU, BR, DK, FI, HU, JP, NO | | | | |
| | AU 8540673 | A1 | 19850924 | AU 1985-40673 | 19850306 |
| | AU 571072 | B2 | 19880331 | | |
| | JP 61501325 | T2 | 19860703 | JP 1985-501264 | 19850306 |
| | JP 06076317 | B4 | 19940928 | | |
| | IL 74535 | A1 | 19881230 | IL 1985-74535 | 19850307 |
| | AT 91233 | E | 19930715 | AT 1985-102607 | 19850307 |
| | ZA 8501765 | A | 19851127 | ZA 1985-1765 | 19850308 |
| | ES 541103 | A1 | 19861016 | ES 1985-541103 | 19850308 |
| | US 4757088 | A | 19880712 | US 1986-939513 | 19861022 |
| | US 4914131 | A | 19900403 | US 1989-338448 | 19890414 |
| PRAI | US 1984-587398 | | 19840308 | | |
| | WO 1985-US362 | | 19850306 | | |
| | EP 1985-102607 | | 19850307 | | |
| | US 1986-939513 | | 19861022 | | |
| | US 1987-67230 | | 19870629 | | |

L20 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS
 AN 1982:168754 CAPLUS
 DN 96:168754
 TI Multivitamin for treating **herpes** infections
 IN Girard, Michele; Baufle, Marie Chantal
 PA Fr.
 SO Fr. Demande, 8 pp.
 CODEN: FRXXBL
 DT Patent
 LA French
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---------------|------|----------|-----------------|----------|
| PI | FR 2484257 | A1 | 19811218 | FR 1980-13665 | 19800616 |
| | FR 2484257 | B3 | 19830311 | | |
| PRAI | FR 1980-13665 | | 19800616 | | |

=> d 120 5 6 all

L20 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS
 AN 1986:45751 CAPLUS
 DN 104:45751
 TI Antiviral pharmaceutical preparations and their use
 IN Haines, Harold Gray; Dickens, Caroline Burgess
 PA Brigham, Dana, USA
 SO Eur. Pat. Appl., 44 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 IC ICM A61K031-16
 ICS A61K031-195
 ICI A61K031-195, A61K031-16
 CC 1-5 (Pharmacology)
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | EP 154344 | A2 | 19850911 | EP 1985-102607 | 19850307 |
| | EP 154344 | A3 | 19900613 | | |
| | EP 154344 | B1 | 19930707 | | |
| | R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE | | | | |
| | US 4628063 | A | 19861209 | US 1984-587398 | 19840308 |
| | WO 8503862 | A1 | 19850912 | WO 1985-US362 | 19850306 |
| | W: AU, BR, DK, FI, HU, JP, NO | | | | |
| | AU 8540673 | A1 | 19850924 | AU 1985-40673 | 19850306 |
| | AU 571072 | B2 | 19880331 | | |
| | JP 61501325 | T2 | 19860703 | JP 1985-501264 | 19850306 |
| | JP 06076317 | B4 | 19940928 | | |
| | IL 74535 | A1 | 19881230 | IL 1985-74535 | 19850307 |
| | AT 91233 | E | 19930715 | AT 1985-102607 | 19850307 |
| | ZA 8501765 | A | 19851127 | ZA 1985-1765 | 19850308 |
| | ES 541103 | A1 | 19861016 | ES 1985-541103 | 19850308 |
| | US 4757088 | A | 19880712 | US 1986-939513 | 19861022 |
| | US 4914131 | A | 19900403 | US 1989-338448 | 19890414 |
| PRAI | US 1984-587398 | | 19840308 | | |
| | WO 1985-US362 | | 19850306 | | |
| | EP 1985-102607 | | 19850307 | | |
| | US 1986-939513 | | 19861022 | | |
| | US 1987-67230 | | 19870629 | | |
| AB | Lidocaine or lidocaine-HCl, in combination with panthenol or pantothenic acid, is effective in the treatment of herpes virus infections in humans. Thus, 14 human males suffering from recurring genital | | | | |

herpes applied a lidocaine-HCl 40, dexpanthenol 50 mg/mL ointment to the affected areas 3 times a day. The pre-blister itching and pain assocd. with blisters were markedly reduced 15-20 min after the 1st application. All cases treated showed a definite abortion or shortening of the 7-10-day itching, blister, and scab cycle. All blisters cleared up after 2-3 days of application of the lidocaine-HCl ointment.

ST **herpes** treatment lidocaine dexpanthenol; virus **herpes** infection lidocaine dexpanthenol

IT Virus, animal

(**herpes**, infection of humans with, treatment of, lidocaine and dexpanthenol in)

IT Virus, animal

(**herpes simplex**, infection of humans with, treatment of, lidocaine and dexpanthenol in)

IT Virus, animal

(**varicella-zoster**, infection of humans with, treatment of, lidocaine and dexpanthenol in)

IT 73-78-9 **79-83-4** 81-13-0 137-58-6 16485-10-2

RL: BIOL (Biological study)

(**herpes** virus infection treatment with)

L20 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS

AN 1982:168754 CAPLUS

DN 96:168754

TI Multivitamin for treating **herpes** infections

IN Girard, Michele; Baufle, Marie Chantal

PA Fr.

SO Fr. Demande, 8 pp.

CODEN: FRXXBL

DT Patent

LA French

IC A61K031-66; A61K031-07; A61K031-59; A61K031-195; A61K031-335; A61K031-395

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---------------|------|----------|-----------------|----------|
| PI | FR 2484257 | A1 | 19811218 | FR 1980-13665 | 19800616 |
| | FR 2484257 | B3 | 19830311 | | |
| PRAI | FR 1980-13665 | | 19800616 | | |

AB All cases of **herpes** (recurrent, labial, genital) could be treated rapidly and efficiently by a multivitamin compn. contg. vitamin A [11103-57-4] trace, vitamin D3 [67-97-0] trace, vitamin B1 [59-43-8] 1-5, vitamin B2 [83-88-5] 1-5, vitamin B5 [**79-83-4**] 1-5, vitamin B6 [8059-24-3] 0.5-1, vitamin B8 [64060-35-1] 0.01-0.05, vitamin B9 [11096-55-2] 0.05-0.1, vitamin B12 [68-19-9] 0.001-0.002, vitamin C [50-81-7] 20-50, vitamin E [1406-18-4] 2-10, and vitamin PP [11032-50-1] 0.01-0.02 mg.

ST **herpes** treatment multivitamin; vitamin **herpes** infection

IT Vitamins

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(**herpes** infection treatment with, in humans)

IT Virus, animal

(**herpes**, infection with, multivitamin compn. for treatment of, in humans)

IT 50-81-7, biological studies 58-56-0 58-85-5 58-95-7 59-30-3, biological studies 59-43-8, biological studies 67-97-0 68-19-9

79-83-4 83-88-5, biological studies 98-92-0 **137-08-6**

146-17-8 1406-18-4 8059-24-3 11032-50-1 11096-55-2 11103-57-4

64060-35-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(**herpes** infection treatment with multivitamin compn. contg.,
in humans)

=> d his

(FILE 'HOME' ENTERED AT 15:19:02 ON 07 JUL 2003)

FILE 'REGISTRY' ENTERED AT 15:19:14 ON 07 JUL 2003

L1 101 S PANTOTHENIC ACID
L2 2 S VITAMIN B5
L3 2 S VITAMIN B3
L4 1 S L2 NOT L3

FILE 'CAPLUS' ENTERED AT 15:20:40 ON 07 JUL 2003

L5 5882 S L1
E RETROVIRAL
L6 13948 S E1-E6
L7 50063 S HIV
L8 61642 S L7 OR L6
L9 8 S L5 AND L8
L10 21260 S VITAMIN D
L11 33 S L10 AND L8

FILE 'REGISTRY' ENTERED AT 15:37:52 ON 07 JUL 2003

L12 1 S 17097-76-6/RN
SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

FILE 'CAPLUS' ENTERED AT 15:40:49 ON 07 JUL 2003

L13 5412 S L2
L14 11658 S L3
L15 4 S L13 AND L8
L16 19 S L14 AND L8
L17 15 S L16 NOT L15
L18 27587 S HERPES OR HSV OR HHSV OR CMV
L19 2073 S L18 AND L8
L20 6 S L18 AND L5

=> d his

(FILE 'HOME' ENTERED AT 15:19:02 ON 07 JUL 2003)

FILE 'REGISTRY' ENTERED AT 15:19:14 ON 07 JUL 2003

L1 101 S PANTOTHENIC ACID
L2 2 S VITAMIN B5
L3 2 S VITAMIN B3
L4 1 S L2 NOT L3

FILE 'CAPLUS' ENTERED AT 15:20:40 ON 07 JUL 2003

L5 5882 S L1
E RETROVIRAL
L6 13948 S E1-E6
L7 50063 S HIV
L8 61642 S L7 OR L6
L9 8 S L5 AND L8
L10 21260 S VITAMIN D
L11 33 S L10 AND L8

FILE 'REGISTRY' ENTERED AT 15:37:52 ON 07 JUL 2003
L12 1 S 17097-76-6/RN
SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

FILE 'CAPLUS' ENTERED AT 15:40:49 ON 07 JUL 2003
L13 5412 S L2
L14 11658 S L3
L15 4 S L13 AND L8
L16 19 S L14 AND L8
L17 15 S L16 NOT L15
L18 27587 S HERPES OR HSV OR HHSV OR CMV
L19 2073 S L18 AND L8
L20 6 S L18 AND L5

=> d 116 10-19

L16 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2003 ACS
AN 1997:606368 CAPLUS
DN 127:272289
TI Apoptotic DNA fragmentation, and its in vitro prevention by nicotinamide, in lymphocytes from **HIV-1**-seropositive patients and in **HIV-1**-infected MT-4 cells
AU Savarino, A.; Martini, C.; Orofino, G. C.; Cantamessa, C.; Castelli, L.; Pich, P. G.; Sinicco, A.; Pugliese, A.
CS Department of Medical and Surgical Sciences, Section of Infectious Diseases, University of Turin, Italy
SO Cell Biochemistry and Function (1997), 15(3), 171-179
CODEN: CBFUDH; ISSN: 0263-6484
PB Wiley
DT Journal
LA English

L16 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2003 ACS
AN 1997:79334 CAPLUS
DN 126:143042
TI Investigation of the potential role of membrane CD38 in protection against cell death induced by **HIV-1**
AU Savarino, A.; Pugliese, A.; Martini, C.; Pich, P. G.; Pescarmona, G. P.; Malavasi, F.
CS Department of Medical and Surgical Sciences, University of Torino, Turin, Italy
SO Journal of Biological Regulators and Homeostatic Agents (1996), 10(1), 13-18
CODEN: JBRAER; ISSN: 0393-974X
PB Wichtig
DT Journal
LA English

L16 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2003 ACS
AN 1996:256739 CAPLUS
DN 124:299031
TI Growth control for cells encapsulated within bioartificial organs
IN Schinstine, Malcolm; Shoichet, Molly S.; Gentile, Frank T.; Hammang, Joseph P.; Holland, Laura M.; Cain, Brian M.; Doherty, Edward J.; Winn, Shelley R.; Aebischer, Patrick
PA Cytotherapeutics, Inc., USA
SO PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9602646 | A2 | 19960201 | WO 1995-US9281 | 19950720 |
| | WO 9602646 | A3 | 19960517 | | |
| | W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT | | | | |
| | RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | US 5935849 | A | 19990810 | US 1994-279773 | 19940720 |
| | US 5843431 | A | 19981201 | US 1995-432698 | 19950509 |
| | AU 9531422 | A1 | 19960216 | AU 1995-31422 | 19950720 |
| | AU 698624 | B2 | 19981105 | | |
| | EP 771350 | A1 | 19970507 | EP 1995-927373 | 19950720 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| | JP 10506266 | T2 | 19980623 | JP 1995-505271 | 19950720 |
| | BR 9508312 | A | 19990601 | BR 1995-8312 | 19950720 |
| | NO 9700156 | A | 19970320 | NO 1997-156 | 19970114 |
| | FI 9700217 | A | 19970117 | FI 1997-217 | 19970117 |
| PRAI | US 1994-279773 | A | 19940720 | | |
| | US 1995-432698 | A | 19950509 | | |
| | WO 1995-US9281 | W | 19950720 | | |

L16 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2003 ACS

AN 1995:958459 CAPLUS

DN 124:7065

TI Biochemically active agents for chemical catalysis and cell receptor activation

IN Kossovsky, Nir; Sponsler, Edward; Gelman, Andrew; Rajguru, Samir

PA The Regents of the University of California, USA

SO U.S., 13 pp. Cont.-in-part of U.S. 5,334,394.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 10

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | US 5460830 | A | 19951024 | US 1993-145870 | 19931101 |
| | US 5219577 | A | 19930615 | US 1990-542255 | 19900622 |
| | US 5178882 | A | 19930112 | US 1991-690601 | 19910424 |
| | JP 05255111 | A2 | 19931005 | JP 1991-178805 | 19910624 |
| | JP 2932406 | B2 | 19990809 | | |
| | US 5334394 | A | 19940802 | US 1993-199 | 19930104 |
| | US 5462750 | A | 19951031 | US 1994-225100 | 19940408 |
| | WO 9512392 | A1 | 19950511 | WO 1994-US12515 | 19941031 |
| | W: CA, JP | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| | CA 2174244 | AA | 19950511 | CA 1994-2174244 | 19941031 |
| | EP 726767 | A1 | 19960821 | EP 1995-901094 | 19941031 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| | JP 09504790 | T2 | 19970513 | JP 1994-513349 | 19941031 |
| PRAI | US 1990-542255 | | 19900622 | | |
| | US 1991-690601 | | 19910424 | | |
| | US 1993-199 | | 19930104 | | |
| | US 1993-986 | | 19930106 | | |
| | US 1993-145870 | | 19931101 | | |
| | US 1993-146536 | | 19931101 | | |
| | US 1993-147751 | | 19931104 | | |
| | WO 1994-US12515 | | 19941031 | | |

L16 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2003 ACS
AN 1995:673568 CAPLUS
DN 123:109959
TI **HIV** infection decreases intracellular nicotinamide adenine dinucleotide [NAD]
AU Murray, Michael F.; Nghiem, Michael; Srinivasan, Alagarsamy
CS Dep. Med., Univ. PA Sch. Med., Philadelphia, PA, USA
SO Biochemical and Biophysical Research Communications (1995), 212(1), 126-31
CODEN: BBRCA9; ISSN: 0006-291X
PB Academic
DT Journal
LA English

L16 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2003 ACS
AN 1995:590755 CAPLUS
DN 123:357
TI Nicotinamide inhibits **HIV-1** in both acute and chronic in vitro infection
AU Murray, Michael F.; Srinivasan, Alagarsamy
CS Department of Medicine, University of PA School of Medicine, Philadelphia, Panama
SO Biochemical and Biophysical Research Communications (1995), 210(3), 954-9
CODEN: BBRCA9; ISSN: 0006-291X
PB Academic
DT Journal
LA English

L16 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2003 ACS
AN 1995:556533 CAPLUS
DN 123:143841
TI Synthesis and antiviral evaluation of fluorinated dipyridodiazepinones and dipyridodiazepines (nevirapine derivatives)
AU Boyode, B. P.; Sinet, M.; Barese, A.; Forestier-Roux, M.-A.; Condom, R.; Ayi, I. A.; Kirn, A.; Moog, C.; Guedj, R.
CS Faculte Sciences, Universite Nice-Sophia Antipolis, Nice, F-06108, Fr.
SO Antiviral Chemistry & Chemotherapy (1995), 6(3), 162-8
CODEN: ACCHEH; ISSN: 0956-3202
PB Blackwell
DT Journal
LA English

L16 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2003 ACS
AN 1991:622844 CAPLUS
DN 115:222844
TI Inhibitors of ADP-ribosylation as antiviral drugs: experimental study on the model of **HIV** infection
AU Krasil'nikov, I. I.; Kalnina, L. B.; Korneeva, M. N.; Nosik, D. N.; Zlobin, A. Yu.; Vladimirov, V. G.; L'vov, D. K.
CS Inst. Virusol. im. Ivanovskogo, Moscow, USSR
SO Voprosy Virusologii (1991), 36(3), 216-18
CODEN: VVIRAT; ISSN: 0507-4088
DT Journal
LA Russian

L16 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2003 ACS
AN 1990:610545 CAPLUS
DN 113:210545
TI Micronutrient status and human immunodeficiency virus (**HIV**) infection
AU Bogden, John D.; Baker, Herman; Frank, Oscar; Perez, George; Kemp, Francis; Bruening, Kay; Louria, Donald

CS New Jersey Med. Sch., Univ. Med. Dent., Newark, NJ, 07103-2757, USA
 SO Annals of the New York Academy of Sciences (1990), 587(Micronutr. Immune
 Funct./Cytokines Metab.), 189-95
 CODEN: ANYAA9; ISSN: 0077-8923
 DT Journal
 LA English

L16 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2003 ACS
 AN 1990:151841 CAPLUS
 DN 112:151841
 TI Preparation of glycerophosphate derivatives as animal virucides
 IN Shenfeld, Avner
 PA Scienscope International N. V., Neth.
 SO Eur. Pat. Appl., 22 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| PI EP 316117 | A1 | 19890517 | EP 1988-310391 | 19881104 |
| R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE | | | | |
| WO 8904314 | A1 | 19890518 | WO 1988-NL48 | 19881102 |
| W: AU, BB, BG, BR, DK, FI, HU, JP, KP, KR, LK, MC, MG, MW, NL, NO,
RO, SD, SU | | | | |
| RW: BJ, CF, CG, CM, GA, ML, MR, SN, TD, TG | | | | |
| AU 8826199 | A1 | 19890601 | AU 1988-26199 | 19881102 |
| JP 02502096 | T2 | 19900712 | JP 1988-508750 | 19881102 |
| FI 8903279 | A | 19890705 | FI 1989-3279 | 19890705 |
| PRAI IL 1987-84387 | | 19871106 | | |
| WO 1988-NL48 | | 19881102 | | |
| OS MARPAT 112:151841 | | | | |

=> d 116 5-9

L16 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:51504 CAPLUS
 DN 136:112623
 TI Zinc finger motif sequences from herpes simplex virus protein IE63 and
 uses thereof in drug screening for treating herpesvirus infection
 IN Clements, John Barklie; MacLean, Alasdair Roderick
 PA The University Court of the University of Glasgow, UK
 SO PCT Int. Appl., 43 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| PI WO 2002004492 | A2 | 20020117 | WO 2001-GB3114 | 20010711 |
| WO 2002004492 | A3 | 20020510 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 1299725 | A2 | 20030409 | EP 2001-949666 | 20010711 |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
PRAI GB 2000-16890 A 20000711
WO 2001-GB3114 W 20010711

L16 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2003 ACS
AN 2001:504998 CAPLUS
DN 136:273127
TI Increased plasma tryptophan in **HIV**-infected patients treated
with pharmacologic doses of nicotinamide
AU Murray, M. F.; Langan, M.; MacGregor, R. R.
CS Department of Medicine, Brigham and Women's Hospital, Harvard University,
Boston, MA, USA
SO Nutrition (New York, NY, United States) (2001), 17(7/8), 654-656
CODEN: NUTRER; ISSN: 0899-9007
PB Elsevier Science Inc.
DT Journal
LA English
RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2003 ACS
AN 2001:6065 CAPLUS
DN 134:37051
TI Method for immune-system strengthening and development of a lipid
transporter for anti-**HIV** and antibacterial gene therapy
IN Worm, Richard; Correa, Michel; Mavoungou, Donatien
PA Can.
SO Fr. Demande, 16 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI FR 2792201 A1 20001020 FR 1999-4706 19990415
FR 2792201 B1 20011102
PRAI FR 1999-4706 19990415

L16 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2003 ACS
AN 1999:454270 CAPLUS
DN 131:82943
TI Compositions and methods for identifying therapeutic agents and for
treating cells having double minute DNA
IN Wahl, Geoffrey M.; Shepard, H. Michael; Shimizu, Noriaki
PA Newbiotics, Inc., USA; The Salk Institute; Kanda, Teru
SO PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----|---|------|----------|-----------------|----------|
| PI | WO 9935292 | A1 | 19990715 | WO 1999-US601 | 19990111 |
| W: | AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM | | | | |
| RW: | GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, | | | | |

CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 CA 2318380 AA 19990715 CA 1999-2318380 19990111
 AU 9922217 A1 19990726 AU 1999-22217 19990111
 EP 1070140 A1 20010124 EP 1999-902175 19990111
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 BR 9906926 A 20020115 BR 1999-6926 19990111
 JP 2002510033 T2 20020402 JP 2000-527673 19990111
 PRAI US 1998-71146P P 19980112
 US 1998-77644P P 19980311
 WO 1999-US601 W 19990111
 OS MARPAT 131:82943
 RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2003 ACS
 AN 1998:661494 CAPLUS
 DN 129:298375
 TI Antimicrobial prevention and treatment of human immunodeficiency virus and
 other infectious diseases
 IN Squires, Meryl
 PA USA
 SO PCT Int. Appl., 99 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 5

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9842188 | A1 | 19981001 | WO 1998-US5792 | 19980324 |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG,
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,
FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | US 6350784 | B1 | 20020226 | US 1997-824041 | 19970326 |
| | AU 9867718 | A1 | 19981020 | AU 1998-67718 | 19980324 |
| | AU 727339 | B2 | 20001207 | | |
| | BR 9807892 | A | 20000222 | BR 1998-7892 | 19980324 |
| | EP 980203 | A1 | 20000223 | EP 1998-913086 | 19980324 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO | | | | |
| | EE 9900436 | A | 20000417 | EE 1999-436 | 19980324 |
| | NZ 500002 | A | 20010928 | NZ 1998-500002 | 19980324 |
| | JP 2001527541 | T2 | 20011225 | JP 1998-545926 | 19980324 |
| | NO 9904639 | A | 19991124 | NO 1999-4639 | 19990924 |
| | MX 9908750 | A | 20000331 | MX 1999-8750 | 19990924 |
| | BG 63612 | B1 | 20020731 | BG 1999-103786 | 19991007 |
| PRAI | US 1997-824041 | A | 19970326 | | |
| | US 1996-600217 | A2 | 19960212 | | |
| | US 1996-646988 | A2 | 19960508 | | |
| | WO 1998-US5792 | W | 19980324 | | |

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 116 19 all

L16 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2003 ACS

AN 1990:151841 CAPLUS
DN 112:151841
TI Preparation of glycerophosphate derivatives as animal virucides
IN Shenfeld, Avner
PA Scienscope International N. V., Neth.
SO Eur. Pat. Appl., 22 pp.
CODEN: EPXXDW
DT Patent
LA English
IC ICM C07F009-10
ICS C07F009-09; C07F009-58; A61K031-66
CC 1-5 (Pharmacology)
Section cross-reference(s): 27

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | EP 316117 | A1 | 19890517 | EP 1988-310391 | 19881104 |
| | R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE | | | | |
| | WO 8904314 | A1 | 19890518 | WO 1988-NL48 | 19881102 |
| | W: AU, BB, BG, BR, DK, FI, HU, JP, KP, KR, LK, MC, MG, MW, NL, NO, RO, SD, SU | | | | |
| | RW: BJ, CF, CG, CM, GA, ML, MR, SN, TD, TG | | | | |
| | AU 8826199 | A1 | 19890601 | AU 1988-26199 | 19881102 |
| | JP 02502096 | T2 | 19900712 | JP 1988-508750 | 19881102 |
| | FI 8903279 | A | 19890705 | FI 1989-3279 | 19890705 |
| PRAI | IL 1987-84387 | | 19871106 | | |
| | WO 1988-NL48 | | 19881102 | | |
| OS | MARPAT 112:151841 | | | | |
| AB | The acylglycerophosphate esters R1OCH2CH(OR2)CH2OP(O)(O-)GAzR3 [R1, R2 = H, fatty acyl; A = CH2, polymethylene, oxapolymethylene, thiapolymethylene, etc. R3 = (un)substituted Ph or pyridinium, etc.; G = O, S; Z = 0, 1-18] are prep'd. as virucides, suitable for treating human immunodeficiency virus (HIV) infections. 2-Hydroxyethyl-1-nicotinamide chloride (prepn. given) was transphosphatidylated enzymically, by the method of Eibel and Kovatchev (1981), to give phosphatidyl-2-hydroxyethyl-1-nicotinamide (I). I (20 .mu.g/mL) totally controlled HIV , in vitro, as shown by the method of Moore, et al. (1978). | | | | |

ST virucide animal phospholipid; glycerophosphate deriv prepn AIDS drug
IT Phosphatidylethanolamines
RL: RCT (Reactant); RACT (Reactant or reagent)
(acetylation of)
IT Phospholipids, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(virucides, animal)
IT Immunodeficiency
(acquired immune deficiency syndrome, treatment of, with reaction products of acylglycerophosphates with alcs. and thiols)
IT Phosphatidic acids
RL: SPN (Synthetic preparation); PREP (Preparation)
(esters, prepn. of, as animal virucides)
IT Virucides and Virustats
(medical, reaction products of acid glycerophosphates with alcs. or thiols)
IT Phosphatidylethanolamines
RL: SPN (Synthetic preparation); PREP (Preparation)
(reaction products, with acetic anhydride, prepn. of, as animal virucide)
IT **98-92-0**, Nicotinamide
RL: BIOL (Biological study)
(condensation of, with chloroethanol)

IT 107-07-3, 2-Chloroethanol, biological studies
RL: BIOL (Biological study)
(condensation of, with nicotinamide)
IT 126235-31-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and transphosphatidylation of)
IT 58-27-5DP, reaction products with phosphatidylethanolamines 100-51-6DP,
Benzene methanol, reaction products with phosphatidic acids 108-24-7DP,
reaction products with phosphatidylethanolamines 141-79-7DP, reaction
products with phosphatidylethanolamines 126235-31-2DP, reaction products
with phosphatidic acids
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as animal virucide)
IT 58-27-5, Menadione
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with phosphatidylethanolamine)

=> d his

(FILE 'HOME' ENTERED AT 15:19:02 ON 07 JUL 2003)

FILE 'REGISTRY' ENTERED AT 15:19:14 ON 07 JUL 2003

L1 101 S PANTOTHENIC ACID
L2 2 S VITAMIN B5
L3 2 S VITAMIN B3
L4 1 S L2 NOT L3

FILE 'CAPLUS' ENTERED AT 15:20:40 ON 07 JUL 2003

L5 5882 S L1
E RETROVIRAL
L6 13948 S E1-E6
L7 50063 S HIV
L8 61642 S L7 OR L6
L9 8 S L5 AND L8
L10 21260 S VITAMIN D
L11 33 S L10 AND L8

FILE 'REGISTRY' ENTERED AT 15:37:52 ON 07 JUL 2003

L12 1 S 17097-76-6/RN
SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

FILE 'CAPLUS' ENTERED AT 15:40:49 ON 07 JUL 2003

L13 5412 S L2
L14 11658 S L3
L15 4 S L13 AND L8
L16 19 S L14 AND L8
L17 15 S L16 NOT L15
L18 27587 S HERPES OR HSV OR HHSV OR CMV
L19 2073 S L18 AND L8
L20 6 S L18 AND L5

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

| | | |
|--|------------|---------|
| COST IN U.S. DOLLARS' | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| FULL ESTIMATED COST | 83.56 | 212.31 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| CA SUBSCRIBER PRICE | -5.21 | -10.42 |

STN INTERNATIONAL LOGOFF AT 16:01:44 ON 07 JUL 2003

AN 1990:610545 CAPLUS
DN 113:210545
TI Micronutrient status and human immunodeficiency virus (**HIV**)
infection
AU Bogden, John D.; Baker, Herman; Frank, Oscar; Perez, George; Kemp,
Francis; Bruening, Kay; Louria, Donald
CS New Jersey Med. Sch., Univ. Med. Dent., Newark, NJ, 07103-2757, USA
SO Annals of the New York Academy of Sciences (1990), 587(Micronutr. Immune
Funct./Cytokines Metab.), 189-95
CODEN: ANYAA9; ISSN: 0077-8923
DT Journal
LA English
CC 18-1 (Animal Nutrition)
Section cross-reference(s): 14, 15
AB Humans with **HIV** infections generally showed .gtoreq.1 abnormally
low level of plasma micronutrients (e.g. minerals, vitamins). Abnormally
high levels of some micronutrients were also found, but these were
attributed to the ingestion of high supplement amts.
ST micronutrient nutrition human immunodeficiency virus infection;
HIV infection diet micronutrient
IT Carotenes and Carotenoids, biological studies
Trace elements, biological studies
Vitamins
RL: BIOL (Biological study)
(**HIV** virus infection in humans in relation to nutritional
status of)
IT Virus, animal
(human immunodeficiency 1, humans infection by, micronutrient status in
relation to)
IT Nutrients
(micro-, **HIV** virus infection in humans in relation to
nutritional status of)
IT 50-81-7, Vitamin C, biological studies 58-85-5, Biotin 59-30-3, Folic
acid, biological studies 59-43-8, Thiamin, biological studies 59-67-6,
Niacin, biological studies 62-49-7, Choline 68-19-9, Vitamin B12
79-83-4, Pantothenic acid 83-88-5, Riboflavin, biological
studies 87-89-8, Inositol 541-15-1, Carnitine 1406-18-4, Vitamin E
7439-95-4, Magnesium, biological studies 7440-50-8, Copper, biological
studies 7440-66-6, Zinc, biological studies 7440-70-2, Calcium,
biological studies 8059-24-3, Vitamin B6 11103-57-4, Vitamin A
22150-76-1, Biopterin
RL: BIOL (Biological study)
(**HIV** virus infection in humans in relation to nutritional
status of)

AN 1990:610545 CAPLUS
DN 113:210545
TI Micronutrient status and human immunodeficiency virus (**HIV**) infection
AU Bogden, John D.; Baker, Herman; Frank, Oscar; Perez, George; Kemp, Francis; Bruening, Kay; Louria, Donald
CS New Jersey Med. Sch., Univ. Med. Dent., Newark, NJ, 07103-2757, USA
SO Annals of the New York Academy of Sciences (1990), 587(Micronutr. Immune Funct./Cytokines Metab.), 189-95
CODEN: ANYAA9; ISSN: 0077-8923
DT Journal
LA English
CC 18-1 (Animal Nutrition)
Section cross-reference(s): 14, 15
AB Humans with **HIV** infections generally showed .gtoreq.1 abnormally low level of plasma micronutrients (e.g. minerals, vitamins). Abnormally high levels of some micronutrients were also found, but these were attributed to the ingestion of high supplement amts.
ST micronutrient nutrition human immunodeficiency virus infection; **HIV** infection diet micronutrient
IT Carotenes and Carotenoids, biological studies
Trace elements, biological studies
Vitamins
RL: BIOL (Biological study)
(**HIV** virus infection in humans in relation to nutritional status of)
IT Virus, animal
(human immunodeficiency 1, humans infection by, micronutrient status in relation to)
IT Nutrients
(micro-, **HIV** virus infection in humans in relation to nutritional status of)
IT 50-81-7, Vitamin C, biological studies 58-85-5, Biotin 59-30-3, Folic acid, biological studies 59-43-8, Thiamin, biological studies 59-67-6, Niacin, biological studies 62-49-7, Choline 68-19-9, Vitamin B12 79-83-4, Pantothenic acid 83-88-5, Riboflavin, biological studies 87-89-8, Inositol 541-15-1, Carnitine 1406-18-4, Vitamin E 7439-95-4, Magnesium, biological studies 7440-50-8, Copper, biological studies 7440-66-6, Zinc, biological studies 7440-70-2, Calcium, biological studies 8059-24-3, Vitamin B6 11103-57-4, Vitamin A 22150-76-1, Biopterin
RL: BIOL (Biological study)
(**HIV** virus infection in humans in relation to nutritional status of)

AN 1998:661494 CAPLUS
 DN 129:298375
 TI Antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases
 IN Squires, Meryl
 PA USA
 SO PCT Int. Appl., 99 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A01N033-12
 ICS A61K031-14
 CC 1-5 (Pharmacology)
 Section cross-reference(s): 63

FAN.CNT 5

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9842188 | A1 | 19981001 | WO 1998-US5792 | 19980324 |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | US 6350784 | B1 | 20020226 | US 1997-824041 | 19970326 |
| | AU 9867718 | A1 | 19981020 | AU 1998-67718 | 19980324 |
| | AU 727339 | B2 | 20001207 | | |
| | BR 9807892 | A | 20000222 | BR 1998-7892 | 19980324 |
| | EP 980203 | A1 | 20000223 | EP 1998-913086 | 19980324 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | EE 9900436 | A | 20000417 | EE 1999-436 | 19980324 |
| | NZ 500002 | A | 20010928 | NZ 1998-500002 | 19980324 |
| | JP 2001527541 | T2 | 20011225 | JP 1998-545926 | 19980324 |
| | NO 9904639 | A | 19991124 | NO 1999-4639 | 19990924 |
| | MX 9908750 | A | 20000331 | MX 1999-8750 | 19990924 |
| | BG 63612 | B1 | 20020731 | BG 1999-103786 | 19991007 |
| PRAI | US 1997-824041 | A | 19970326 | | |
| | US 1996-600217 | A2 | 19960212 | | |
| | US 1996-646988 | A2 | 19960508 | | |
| | WO 1998-US5792 | W | 19980324 | | |

AB An improved medical treatment and medicine is provided to quickly and safely resolve **HIV** and other microbial infections. The inexpensive medicine can be self administered and maintained for the prescribed time. The attractive medicine comprises an antimicrobial conc. comprising microbe inhibitors, phytochems. or isolates. Desirably, the effective medicine comprises a surfactant and an aq. carrier or solvent and a nutrient. In the preferred form, the medicine comprises: Echinacea and Commiphora myrrha phytochems., benzalkonium chloride, a sterile water soln., and folic acid.

ST phytochem nutrient antimicrobial **HIV**; Echinacea Commiphora phytochem surfactant antimicrobial **HIV**; folic acid phytochem antimicrobial **HIV**

IT Labia
 Lip
 Lymph node
 Lymphatic system
 T cell (lymphocyte)
 (administration to; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkylbenzyldimethyl, bromides; antimicrobial prevention and treatment
of human immunodeficiency virus and other infectious diseases)

IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkylbenzyldimethyl, chlorides; antimicrobial prevention and treatment
of human immunodeficiency virus and other infectious diseases)

IT Surfactants
(amphoteric; antimicrobial prevention and treatment of human
immunodeficiency virus and other infectious diseases)

IT Bacilli
(anaerobic; antimicrobial prevention and treatment of human
immunodeficiency virus and other infectious diseases)

IT Allium

Anise

Arctostaphylos

Artemisia

Baptisia

Calendula

Capsicum

Carum

Compositae (Asteraceae)

Coriandrum

Echinacea angustifolia

Echinacea atrabactilus

Echinacea pallida

Echinacea purpurea

Echinacea vegetalis

Eucalyptus

Eugenia mytacea

Gentian (Gentiana)

Inula

Juniper (Juniperus)

Labiatae (Lamiaceae)

Meliosma

Mentha

Mentha aquatica hypeuria

Myroxylon

Origanum

Parthenium integrifolium

Plantago

Rosemary

Ruta

Sage (Salvia)
(antimicrobial isolates of; antimicrobial prevention and treatment of
human immunodeficiency virus and other infectious diseases)

IT Adenoviridae

Antibacterial agents

Antimicrobial agents

Antiviral agents

Arbovirus

Arenavirus

Bird (Aves)

Cat (Felis catus)

Cattle

Commiphora erythraea

Commiphora molmol

Commiphora myrrha

Coronavirus

Cytomegalovirus

Dog (Canis familiaris)

Drug delivery systems
Gums and Mucilages
Horse (*Equus caballus*)
Human herpesvirus 1
Human herpesvirus 2
Human herpesvirus 3
Human herpesvirus 4
Human immunodeficiency virus
Human parainfluenza virus
Influenza virus
Livestock
Mycobacterium
Nutrients
Papillomavirus
Picornaviridae
Rodent
Sexually transmitted diseases
Sheep
Staphylococcus
Streptococcus
Surfactants
Swine
(antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Amides, biological studies
Anthocyanins
Enzymes, biological studies
Natural products, pharmaceutical
Polyacetylenes, biological studies
Polysaccharides, biological studies
Proteins, general, biological studies
Sesquiterpenes
Tannins
Vitamins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Encephalitis
Meningitis
(bacterial and viral; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Detergents
Surfactants
(cationic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Inflammation
(cellulitis; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Polyacetylenes, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(derivs.; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Vitamins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fat-sol.; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(injections; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Mouth
(mucosa, administration to; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(nasal; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Surfactants
(nonionic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(ophthalmic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Animal tissue
(periacinal, administration to; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Plant (Embryophyta)
(phytochems.; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Intestine
(rectum, anus, administration to; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(sublingual; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(surfactant; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Carboxylic acids, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetraenoic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(topical, and systemic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Drug delivery systems
(vaginal; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Vitamins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(water-sol.; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Surfactants
(zwitterionic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT 50-81-7, Ascorbic acid, biological studies 57-10-3, Hexadecanoic acid, biological studies 57-88-5, Cholesterol, biological studies 58-86-6, Xylose, biological studies 59-23-4, Galactose, biological studies 59-30-3, Folic acid, biological studies 59-43-8, Thiamin, biological studies 59-67-6, Niacin, biological studies 64-19-7, Acetic acid, biological studies 68-19-9, Vitamin B12 76-49-3, Bornyl acetate 79-83-4, Vitamin B5 80-56-8, .alpha.-Pinene 83-46-5, .beta.-Sitosterol 83-48-7, Stigmasterol 83-88-5, Riboflavin, biological studies 87-44-5, Caryophyllene 87-69-4, biological studies

97-53-0, Eugenol 104-55-2, Cinnamaldehyde 108-39-4, biological studies
112-85-6D, Docosanoic acid, derivs. 117-39-5, Quercetin 121-33-5,
Vanillin 122-03-2, Cumarinaldehyde 127-91-3, .beta.-Pinene 138-86-3,
Limonene 147-81-9, Arabinose 153-18-4, Rutin 327-97-9, Chlorogenic
acid 331-39-5, Caffeic acid 331-39-5D, Caffeic acid, esters 474-58-8
474-62-4, Campesterol 480-10-4, Kaempferol-3-glucoside 482-35-9,
Quercetin-3-glucoside 482-36-0 491-70-3, Luteolin 495-62-5,
.gamma.-Bisabolene 504-97-2, Echinacein 507-70-0, Borneol 520-18-3,
Kaempferol 520-36-5, Apigenin 534-61-2, Isochlorogenic acid
536-60-7, Cumaric alcohol 548-75-4, Quercetagetin-7-glucoside 563-83-7
593-50-0, n-Triacontanol 604-80-8 638-96-0, .alpha.-Amyrone
639-99-6, Elemol 643-20-9D, Pyrrolizidine, alkaloid 1139-30-6,
Caryophyllene epoxide 1406-16-2, Vitamin D 1406-18-4, Vitamin E
2450-53-5, 3,5-Dicaffeoylquinic acid 3562-36-5, Pontica epoxide
3615-41-6, Rhamnose 3812-32-6, Carbonate, biological studies
3943-97-3, Methyl p-hydroxycinnamate 4120-73-4, 4-O-Methylglucuronic
acid 5373-11-5, Luteolin-7-glucoside 5937-48-4, 3-epi-.alpha.-Amyrin
6537-80-0, Chicoric acid 6556-12-3, Glucuronic acid 7235-40-7,
.beta.-Carotene 7439-89-6, Iron, biological studies 7439-95-4,
Magnesium, biological studies 7439-96-5, Manganese, biological studies
7440-09-7, Potassium, biological studies 7440-23-5, Sodium, biological
studies 7440-48-4, Cobalt, biological studies 7440-70-2, Calcium,
biological studies 7723-14-0, Phosphorus, biological studies
7782-49-2, Selenium, biological studies 8001-18-1, Echinacin
8059-24-3, Vitamin B6 9005-80-5, Inulin 9014-63-5D, Xylan, derivs.
9036-66-2, Arabinogalactan 9040-28-2, 4-O-Methylglucuronoarabinoxylan
11006-56-7, Vitamin B15 11103-57-4, Vitamin A 12001-79-5, Vitamin K
12627-13-3, Silicate 13360-61-7, 1-Pentadecene 14808-79-8, Sulfate,
biological studies 16887-00-6, Chloride, biological studies
17627-44-0, .alpha.-Bisabolene 17650-84-9 18668-90-1,
8-Pentadecen-2-one 18794-84-8, .beta.-Farnesene 19912-61-9,
Furanodiene 20493-56-5, Curzerenone 23986-74-5, Germacrene D
24268-41-5, Furanodienone 24738-51-0 25067-58-7, Polyacetylene
25067-58-7D, Polyacetylene, derivs. 27214-55-7, Quercetin-3-xyloside
28028-64-0, Germacrene 29350-73-0, Cadinene 30964-13-7, Cynarin
36129-21-2 39007-92-6, Commiferin 47705-70-4 52525-35-6 57378-72-0
59440-97-0, Echinolone 61276-17-3, Verbascoside 67879-58-7
69350-61-4, Epishybunol 74282-22-7 75081-19-5, Pentadecadiene
76963-26-3 80151-77-5, Tussilagine 82854-37-3, Echinacoside
84744-28-5 91108-32-6, Isotussilagine 94977-38-5 99119-75-2
99119-76-3 116752-09-1 116752-10-4 117841-81-3 118853-85-3
125199-93-1 148879-89-4, Commiphorinic acid 149531-55-5,
.alpha.-Commiphoric acid 149531-56-6, .beta.-Commiphoric acid
149531-57-7, .gamma.-Commiphoric acid 162666-19-5, Inuloidin
205510-62-9, Echinacin B 214041-69-7 214041-70-0 214041-71-1
214041-72-2 214041-73-3 214405-10-4, Heerabolene 214405-11-5,
.alpha.-Heerabomyrrhol 214405-12-6, .beta.-Heerabomyrrhol 214405-13-7,
Heeraboresene 214405-44-4, Viracea 1 214405-45-5, Viracea 2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)

(antimicrobial prevention and treatment of human immunodeficiency virus
and other infectious diseases)

IT 120-32-1, o-Benzyl-p-chlorophenol 139-07-1, Lauryldimethylbenzylammonium
chloride 5538-94-3, Dioctyldimethylammonium chloride 7173-51-5,
Didecyldimethylammonium chloride 32426-11-2, Octyldodecyldimethylammonium
chloride

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antimicrobial prevention and treatment of human immunodeficiency virus
and other infectious diseases)

IT 12001-76-2, Vitamin B

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(complex; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT 79-14-1D, Glycolic acid, derivs.

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(surfactant; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Bryant; US 4797420 A 1989 CAPLUS
- (2) Hempel; DE 3521143 A1 CAPLUS Acc No 1987:483909 1986 CAPLUS
- (3) Silverman; US 5455033 A 1995
- (4) Tyle, R; "The Honest Herbal, A Sensible Guide to the Use of Herbs and Related Remedies", 3rd Edition 1993, P115
- (5) Tyler, V; Herbs of choice, The Therapeutic Use of Phytomedicinals 1994, P181
- (6) Wainberg; Arch AIDS Res, CAPLUS Acc No 1988:147004 1987, V1(1), P57 CAPLUS

AN 1996:682599 CAPLUS
DN 126:153113
TI The effect of 1,25-vitamin D3 on maturation of monocytes from **HIV**-infected patients varies with degree of immunodeficiency
AU Haug, C. J.; Mueller, F.; Rollag, H.; Aukrust, P.; Degre, M.; Froeland, S.
S.
CS Kaptein W. Wilhelmsen og Frues Inst. Bacteriol., Univ. Oslo, Oslo, N-0027, Norway
SO APMIS (1996), 104(7-8), 539-548
CODEN: APMSEL; ISSN: 0903-4641
PB Munksgaard
DT Journal
LA English
CC 2-10 (Mammalian Hormones)
AB The active metabolite of **vitamin D**, 1,25-dihydroxyvitamin D3 (1,25D), has been shown to induce monocyte-to-macrophage maturation in vitro as well as monocytic differentiation of bone marrow precursors and monocytic leukemic cell lines. In this study the authors assessed whether 1,25D could improve the maturation defect the authors have previously demonstrated in monocytes from AIDS patients. In vitro growth and maturation of monocytes from 10 controls, 15 asymptomatic **HIV** pos. (CDC group II or III) and 13 symptomatic **HIV** pos. (CDC group IV) was examd. by assessing cellular morphol., differentiation, adherence and protein content. Cells were cultured for 10 days with or without addn. of 1,25D at a concn. of 100 pg/mL. In addn., patients were monitored clin. and by immunol. parameters and **HIV** p24 antigen in serum. The present study showed that addn. of 1,25D significantly improved the growth and maturation in both patient and control groups. There was a significant neg. correlation between response to 1,25D and CD4+ lymphocyte count in blood in **HIV**-infected patients. A greater response to 1,25D was seen in monocytes from patients with advanced immunodeficiency and symptomatic disease than in monocytes from asymptomatic patients. However, in the most advanced cases of **HIV** infection with serious ongoing opportunistic infections the response to 1,25D was very poor, possibly reflecting profound and incorrigible dysfunction of monocytes.
ST dihydroxyvitamin D3 monocyte macrophage HIV1 AIDS
IT AIDS (disease)
Human immunodeficiency virus 1
Immunodeficiency
Macrophage
Monocyte
(effect of 1,25-vitamin D3 on maturation of monocytes from **HIV**-infected humans varies with degree of immunodeficiency)
IT 32222-06-3, Ro 21-5535
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effect of 1,25-vitamin D3 on maturation of monocytes from **HIV**-infected humans varies with degree of immunodeficiency)